<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>MVA85A vaccine to enhance BCG for preventing tuberculosis - Kashangura, R - 2019 | Cochrane Library</title> <meta content="MVA85A vaccine to enhance BCG for preventing tuberculosis - Kashangura, R - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012915.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="MVA85A vaccine to enhance BCG for preventing tuberculosis - Kashangura, R - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012915.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012915.pub2" name="dc.identifier" scheme="DOI"/> <meta content="MVA85A vaccine to enhance BCG for preventing tuberculosis" name="citation_title"/> <meta content="Rufaro Kashangura&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Nhlangano Health Centre" name="citation_author_institution"/> <meta content="rufarokash12@yahoo.co.uk" name="citation_author_email"/> <meta content="Sophie Jullien&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Jigme Dorji Wangchuck National Referral Hospital" name="citation_author_institution"/> <meta content="Paul Garner" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Samuel Johnson" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD012915.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/04/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012915.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012915.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012915.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*BCG Vaccine; HIV Seropositivity [complications, immunology]; Primary Prevention; Randomized Controlled Trials as Topic; Tuberculosis [*prevention &amp; control]; *Tuberculosis Vaccines; Vaccines, DNA" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012915.pub2&amp;doi=10.1002/14651858.CD012915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012915\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012915\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","fr","hr","fa"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD012915.pub2",title:"MVA85A vaccine to enhance BCG for preventing tuberculosis",firstPublishedDate:"Apr 30, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012915.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012915.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012915.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012915.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012915.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012915.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012915.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012915.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012915.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012915.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4610 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012915.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-sec-0030"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-sec-0031"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/appendices#CD012915-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/table_n/CD012915StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/table_n/CD012915StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">MVA85A vaccine to enhance BCG for preventing tuberculosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information#CD012915-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rufaro Kashangura</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information#CD012915-cr-0003">Sophie Jullien</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information#CD012915-cr-0004">Paul Garner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information#CD012915-cr-0005">Samuel Johnson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information/en#CD012915-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 April 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012915.pub2">https://doi.org/10.1002/14651858.CD012915.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012915-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012915-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012915-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012915-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012915-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012915-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012915-abs-0001" lang="en"> <section id="CD012915-sec-0001"> <h3 class="title" id="CD012915-sec-0001">Background</h3> <p>Tuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette‐Guérin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector vaccine produced to prevent tuberculosis. </p> </section> <section id="CD012915-sec-0002"> <h3 class="title" id="CD012915-sec-0002">Objectives</h3> <p>To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.</p> </section> <section id="CD012915-sec-0003"> <h3 class="title" id="CD012915-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Diseases Group Specialized Register; Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); Embase (Ovid); and four other databases. We searched the WHO ICTRP and ClinicalTrials.gov. All searches were run up to 10 May 2018. </p> </section> <section id="CD012915-sec-0004"> <h3 class="title" id="CD012915-sec-0004">Selection criteria</h3> <p>We evaluated randomized controlled trials of MVA85A vaccine given with BCG in people regardless of age or HIV status. </p> </section> <section id="CD012915-sec-0005"> <h3 class="title" id="CD012915-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the eligibility and risk of bias of trials, and extracted and analyzed data. The primary outcome was active tuberculosis disease. We summarized dichotomous outcomes using risk ratios (RR) and risk differences (RD), with 95% confidence intervals (CI). Where appropriate, we combined data in meta‐analyses. Where meta‐analysis was inappropriate, we summarized results narratively. </p> </section> <section id="CD012915-sec-0006"> <h3 class="title" id="CD012915-sec-0006">Main results</h3> <p>The search identified six studies relating to four Phase 2 randomized controlled trials enrolling 3838 participants. Funding was by government bodies, charities, and philanthropic donors. Five studies included infants, one of them infants born to HIV‐positive mothers. One study included adults living with HIV. All trials included authors from Oxford University who led the laboratory development of the vaccine. Participants received intradermal MVA85A after BCG in some studies, and before selective deferred BCG in HIV‐exposed infants. </p> <p>The largest trial in 2797 African children was well conducted with low risk of bias for most parameters. Risk of bias was uncertain for selective reporting because there were no precise case definition endpoints for active tuberculosis published prior to the trial analysis. </p> <p>MVA85A added to BCG compared to BCG alone probably has no effect on the risk of developing microbiologically confirmed tuberculosis (RR 0.97, 95% CI 0.58 to 1.62; 3439 participants, 2 trials; moderate‐certainty evidence), or the risk of starting on tuberculosis treatment (RR 1.10, 95% CI 0.92 to 1.33; 3687 participants, 3 trials; moderate‐certainty evidence). MVA85A probably has no effect on the risk of developing latent tuberculosis (RR 1.01, 95% CI 0.85 to 1.21; 3831 participants, 4 trials; moderate‐certainty evidence). Vaccinating people with MVA85A in addition to BCG did not cause life‐threatening serious adverse effects (RD 0.00, 95% CI –0.00 to 0.00; 3692 participants, 3 trials; high‐certainty evidence). Vaccination with MVA85A is probably associated with an increased risk of local skin adverse effects (3187 participants, 3 trials; moderate‐certainty evidence), but not systemic adverse effect related to vaccination (144 participants, 1 trial; low‐certainty evidence). This safety profile is consistent with Phase 1 studies which outlined a transient, superficial reaction local to the injection site and mild short‐lived symptoms such as malaise and fever. </p> </section> <section id="CD012915-sec-0007"> <h3 class="title" id="CD012915-sec-0007">Authors' conclusions</h3> <p>MVA85A delivered by intradermal injection in addition to BCG is safe but not effective in reducing the risk of developing tuberculosis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012915-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012915-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012915-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012915-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012915-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012915-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012915-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012915-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012915-abs-0005" lang="en"> <h3>MVA85A vaccine as a booster to BCG for prevention of tuberculosis</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane review was to evaluate the effectiveness and safety of using MVA85A in addition to BCG compared to using BCG alone for prevention of tuberculosis. </p> <p><b>Key messages</b> </p> <p>MVA85A in addition to BCG showed no added benefit to BCG in prevention of acquiring tuberculosis. </p> <p><b>What was studied in the review?</b> </p> <p>Tuberculosis is an infectious airborne disease which affects the lungs and other organs in the body. It can either be active when a person shows signs and symptoms or has confirmatory tests for tuberculosis or latent when a person has inhaled the bacteria before but does not show signs and symptoms of sickness. Currently, there is only one vaccine licensed for prevention of this disease, which is called BCG. However, the ability for the BCG vaccine to prevent tuberculosis differs in different settings and patient groups resulting in tuberculosis still remaining a problem worldwide despite children being immunized. MVA85A is a vaccine that was investigated for prevention of tuberculosis with the hope that when used in addition to BCG it will improve prevention of people getting tuberculosis. </p> <p><b>What are the main results of this review?</b> </p> <p>After examining the research published up to 10 May 2018, we included six study findings from four randomized controlled trials (clinical trials where people are randomly put into one of two or more treatment groups), enrolling 3838 children and adults. Based on these studies of mostly children and adults living in Africa, MVA85A added to BCG compared to BCG alone probably has no effect on the risk of developing active tuberculosis defined as microbiologically confirmed tuberculosis (moderate‐certainty evidence) or the risk of starting on tuberculosis treatment (moderate‐certainty evidence). MVA85A has no effect on the risk of developing latent tuberculosis (moderate‐certainty evidence). MVA85A does not cause any life‐threatening serious side effects (highly‐certainty evidence). There were more local skin reactions in people vaccinated with MVA85A, however, there was no increase in overall side effects in people given MVA85A. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that have been published up to May 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012915-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012915-sec-0098"></div> <h3 class="title" id="CD012915-sec-0099">Implications for practice</h3> <section id="CD012915-sec-0099"> <p>MVA85A in conjunction with Bacillus Calmette‐Guérin (BCG) has no effect on the risk of developing active or latent tuberculosis. </p> </section> <h3 class="title" id="CD012915-sec-0100">Implications for research</h3> <section id="CD012915-sec-0100"> <p>Researchers should define outcomes precisely before starting the trial. If composite outcomes are developed during the trial, this process needs to be transparent, clearly reported, and published prior to breaking the randomized code. Standardization of outcome measures for tuberculosis vaccine efficacy may make it easier for future researchers in the field and allow easy comparison and meta‐analysis of different study outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012915-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012915-sec-0030"></div> <div class="table" id="CD012915-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">MVA85A compared to placebo for preventing tuberculosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MVA85A compared to placebo for preventing tuberculosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐positive and ‐negative adults and children<br/> <b>Setting:</b> South Africa, Senegal<br/> <b>Intervention:</b> MVA85A<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with MVA85A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active tuberculosis: confirmed by culture or Xpert® MTB/RIF</b> longest reported follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (10 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/> (0.58 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3439<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably made little or no difference to the risk of developing active tuberculosis. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active tuberculosis: started on tuberculosis treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000<br/> (94 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/> (0.92 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3687<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably made little or no difference to the risk of needing to start tuberculosis treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Latent tuberculosis</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000<br/> (97 to 138) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/> (0.85 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3831<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably made little or no difference to the risk of developing latent tuberculosis. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD 0.00</b><br/> (–0.00 to 0.00)<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3692<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG did not cause life‐threatening serious adverse effects. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of any severity (local reactions of the skin)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Vaccination with MVA85A was associated with more reactions at the site of the injection.<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3187<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>h,i,j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably increased the risk of having an adverse reaction related to vaccination at the site of the injection. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of any severity (systemic symptoms)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Adverse events reported included malaise, lethargy, fever, and vomiting although differences between groups were not significant at a 95% CI level.<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>k,l,m</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG may not have been associated with an increase in adverse effects related to vaccination. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events of any severity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>808 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>849 per 1000<br/> (824 to 873) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/> (1.02 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3836<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>n</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccination with MVA85A alone slightly increased the risk of having an adverse event.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BCG:</b> Bacillus Calmette‐Guérin; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RD:</b> risk difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias. The largest trial was at unclear risk of bias due to selective reporting; however, the outcomes presented were unlikely to be affected by this (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>).<br/> <sup>b</sup>Downgraded by one level for imprecision. Few events and wide CIs containing clinically appreciable benefit and harm.<br/> <sup>c</sup>Not downgraded for indirectness. The only trial in HIV‐positive adults was stopped early meaning it was underpowered to detect efficacy (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>). Therefore, evidence of efficacy is more generalizable to infants; however, results in adults were consistent with little or no effect being seen across all endpoints.<br/> <sup>d</sup>Downgraded by one level for imprecision. Broad CI containing little or no effect and clinically appreciable harm.<br/> <sup>e</sup>Not downgraded for risk of bias. The largest trial was at unclear risk of bias due to selective reporting; however, the outcome of latent tuberculosis was unlikely to be affected by this (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>).<br/> <sup>f</sup>Risk difference presented as explained in our result section.<br/> <sup>g</sup>Extensive investigation of the vaccine in Phase 1 studies outlined in the <a href="#CD012915-sec-0031">Background</a> of this review outlined "a transient, superficial reaction local to the injection site and mild short‐lived viral symptoms" consistent with the findings reported in the Phase 2 trials.<br/> <sup>h</sup>Downgraded by one level for imprecision. Broad CIs containing clinically appreciable benefit and harm.<br/> <sup>i</sup>Not downgraded for risk of bias. The largest study reported local adverse events and defined these as solicited by the vaccine (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>).<br/> <sup>j</sup>Not downgraded for heterogeneity. While there might be some heterogeneity between the included trials in terms of time of outcome collection, the outcomes are consistent in favour to placebo as shown in <a href="./references#CD012915-fig-0012" title="">Analysis 1.5</a>.<br/> <sup>k</sup>Downgraded by one level for risk of bias. There were some deficiencies in the trial reporting these outcomes.<br/> <sup>l</sup>Additional safety data from Phase 1 studies in 712 participants did not show any adverse effect signals (see section in <a href="#CD012915-sec-0031">Background</a> of this review).<br/> <sup>m</sup>Downgraded by one level for imprecision. Few events reported in the largest trial (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>), data not disaggregated in the second largest trial (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>).<br/> <sup>n</sup>Not downgraded for inconsistency. I<sup>2</sup> value of 37% judged to be non‐significant heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012915-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012915-sec-0031"></div> <section id="CD012915-sec-0032"> <h3 class="title" id="CD012915-sec-0032">Description of the condition</h3> <p>Tuberculosis is an infectious disease caused by <i>Mycobacterium tuberculosis</i>. It was estimated that 10 million people developed tuberculosis in 2017. Tuberculosis now ranks first, followed by HIV, as the leading cause of death from an infectious disease worldwide killing an estimated 1.6 million people in 2017, including 300,000 people living with HIV. Over 95% of these people were living in low‐ and middle‐income countries (<a href="./references#CD012915-bbs2-0094" title="World Health Organization. Global tuberculosis report 2018. www.who.int/tb/publications/global_report/en/ (accessed 3 January 2018). ">WHO 2018</a>). </p> <p>Tuberculosis can be classed as active when people experience signs or symptoms of tuberculosis or have radiological evidence of it. Tuberculosis can also be classified as latent tuberculosis infection (LTBI) where immunological evidence of previous exposure to <i>M tuberculosis</i> exists without clinical or radiological evidence of the disease (<a href="./references#CD012915-bbs2-0042" title="Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America. American Journal of Respiratory and Critical Care Medicine2000;161(4 Pt 1):1376‐95. ">CDC 2000</a>). Of healthy adults with immunological evidence of previous exposure to <i>M tuberculosis</i>, the overall lifetime risk of progressing to active disease if not treated for the infection is 5% to 10% (<a href="./references#CD012915-bbs2-0051" title="HarriesAD , DyeC . Tuberculosis. Annals of Tropical Medicine and Parasitology2006;100(5‐6):415‐31. ">Harries 2006</a>). Often this happens months or years after the initial infection in response to a weakening of the body's immune system. The probability of developing active disease is higher in HIV‐positive people, people with diabetes, and young children (<a href="./references#CD012915-bbs2-0037" title="BakerMA , HarriesAD , JeonCY , HartJE , KapurA , LönnrothK , et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Medicine2011;9:81. ">Baker 2011</a>; <a href="./references#CD012915-bbs2-0086" title="Perez‐VelezCM , MaraisBJ . Tuberculosis in children. New England Journal of Medicine2012;367(4):348‐61. ">Perez‐Velez 2012</a>; <a href="./references#CD012915-bbs2-0092" title="TiemersmaEW , van derWerfMJ , BorgdorffMW , WilliamsBG , NagelkerkeNJ . Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLOS One2011;6(4):e17601. ">Tiemersma 2011</a>). Fifty percent of infants with evidence of LTBI will progress to active disease if untreated (<a href="./references#CD012915-bbs2-0059" title="MaraisBJ , GieRP , SchaafHS , HesselingAC , ObiharaCC , StarkeJJ , et al. The natural history of childhood intra‐thoracic tuberculosis: a critical review of literature from the pre‐chemotherapy era. International Journal of Tuberculosis and Lung Disease2004;8(4):392‐402. ">Marais 2004</a>). People with LTBI require early diagnosis and treatment to reduce the pool of active tuberculosis cases. This is particularly important in high‐risk groups, such as those coinfected with HIV (<a href="./references#CD012915-bbs2-0091" title="SharmaSK , MohananS , SharmaA . Relevance of latent TB infection in areas of high TB prevalence. Chest2012;142(3):761‐73. ">Sharma 2012</a>). Tuberculosis can be treated with long courses of multiple antibiotics, but the rise of HIV and spread of multidrug‐resistant tuberculosis (MDR‐TB) means that tuberculosis is still one of the largest threats to public health worldwide (<a href="./references#CD012915-bbs2-0094" title="World Health Organization. Global tuberculosis report 2018. www.who.int/tb/publications/global_report/en/ (accessed 3 January 2018). ">WHO 2018</a>). Structural determinants such as rapid urbanization of populations and economic inequalities, social determinants such as poverty and poor housing, alongside biological factors such as HIV and drug‐resistant strains of tuberculosis play a vital role in the spread of tuberculosis through vulnerable populations (<a href="./references#CD012915-bbs2-0045" title="DaftaryA , PadayatchiN . Social constraints to TB/HIV healthcare: accounts from coinfected patients in South Africa. AIDS Care2012;24(12):1480‐6. ">Daftary 2012</a>). </p> <p>The Bacillus Calmette‐Guérin (BCG) vaccine is currently the only available vaccine. Epidemiological studies indicate that it has a protective effect against tuberculosis disease in children, particularly against the more severe forms of the disease such as tuberculosis meningitis or miliary tuberculosis (<a href="./references#CD012915-bbs2-0089" title="RoyA , EisenhutM , HarrisRJ , RodriguesLC , SridharS , HabermannS , et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta‐analysis. BMJ2014;349:g4643. [DOI: 10.1136/bmj.g4643] ">Roy 2014</a>). The effectiveness of BCG differs greatly depending on the site of infection. It has consistent protection against tuberculous meningitis and miliary disease in children but variable protection against pulmonary tuberculosis (<a href="./references#CD012915-bbs2-0035" title="AbubakarI , PimpinL , AritiC , BeynonR , MangtaniP , SterneJA , et al. Systematic review and meta‐analysis of the current evidence on the duration of protection by bacillus Calmette‐Guérin vaccination against tuberculosis. Health Technology Assessment2013;17(37):1‐372, v‐vi. ">Abubakar 2013</a>; <a href="./references#CD012915-bbs2-0044" title="ColditzGA , BerkeyCS , MostellerF , BrewerTF , WilsonME , BurdickE , et al. The efficacy of bacillus Calmette‐Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta‐analyses of the published literature. Paediatrics1995;96(1 Pt 1):29‐35. ">Colditz 1995</a>). As a result, despite many areas achieving high coverage of BCG vaccination, the disease remains a problem, and a new tuberculosis vaccine remains an important global research priority (<a href="./references#CD012915-bbs2-0094" title="World Health Organization. Global tuberculosis report 2018. www.who.int/tb/publications/global_report/en/ (accessed 3 January 2018). ">WHO 2018</a>). </p> <p>Previously it has been impossible to ascertain reliably whether the BCG vaccine protected against active disease or infection with <i>M tuberculosis.</i> This was due to the tuberculin skin test being unable to distinguish between cases of LTBI and people who had been vaccinated with BCG (<a href="./references#CD012915-bbs2-0089" title="RoyA , EisenhutM , HarrisRJ , RodriguesLC , SridharS , HabermannS , et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta‐analysis. BMJ2014;349:g4643. [DOI: 10.1136/bmj.g4643] ">Roy 2014</a>). Therefore, the development and use of interferon γ release assays (IGRA), which can distinguish between tuberculosis infection and vaccination, has proved useful. This has allowed researchers to establish that BCG vaccination reduces the risk of <i>Mycobacterium</i> infection in some settings (<a href="./references#CD012915-bbs2-0047" title="EisenhutM , ParanjothyS , AbubakarI , BracebridgeS , LilleyM , MullaR , et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine2009;27(44):6116‐20. ">Eisenhut 2009</a>). </p> </section> <section id="CD012915-sec-0033"> <h3 class="title" id="CD012915-sec-0033">Description of the intervention</h3> <p>Many researchers and policy makers emphasize that a new effective vaccine could be a major contribution to tuberculosis control and elimination as a public health problem (<a href="./references#CD012915-bbs2-0046" title="deCassanSC , PathanAA , SanderCR , MinassianA , RowlandR , HillAV , et al. Investigating the induction of vaccine‐induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG‐immunized adults vaccinated with a new tuberculosis vaccine, MVA85A. Clinical and Vaccine Immunology2010;17(7):1066‐73. ">de Cassan 2010</a>). There are 12 vaccine candidates in clinical trials: eight in Phase 2 or Phase 3, and four in Phase 1. They include candidates to prevent the development of tuberculosis, and candidates to help improve the outcomes of treatment for tuberculosis disease (<a href="./references#CD012915-bbs2-0094" title="World Health Organization. Global tuberculosis report 2018. www.who.int/tb/publications/global_report/en/ (accessed 3 January 2018). ">WHO 2018</a>). </p> <p>The modified Vaccinia Ankara virus‐expressing antigen 85A (MVA85A) is a viral vector vaccine based on the modified Vaccinia Ankara (MVA) virus. MVA is an attenuated virus that does not replicate in human tissue and, as such, has been used as a platform to encode multiple antigens and allowing development of multivalent vaccines (<a href="./references#CD012915-bbs2-0036" title="AltenburgAF , KreijtzJH , deVriesRD , SongF , FuxR , RimmelzwaanGF , et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses2014;6(7):2735‐61. ">Altenburg 2014</a>). In this case, MVA has had pieces of DNA from <i>M tuberculosis</i> inserted into it<i>,</i> so that it expresses the antigen 85A. This antigen complex is an enzyme that is involved in the cell wall biosynthesis of <i>M tuberculosis</i> and constitutes a vital part of the way in which the bacteria forms its outer mycomembrane. This is important for the viability of the mycobacterium and works as an effective barrier to drug therapies by repelling some antibiotics and preventing them from entering the cell (<a href="./references#CD012915-bbs2-0048" title="FavrotL , GrzegorzewiczAE , LajinessDH , MarvinRK , BoucauJ , IsailovicD , et al. Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen. Nature Communications2013;4:2748. [DOI: 10.1038/ncomms3748] ">Favrot 2013</a>). </p> <p>Immunological studies have shown that a prime boost strategy, where MVA85A is used to boost the effects of BCG, is effective in expanding immune responses specific to <i>M tuberculosis</i> (<a href="./references#CD012915-bbs2-0040" title="BeveridgeNE , PriceDA , CasazzaJP , PathanAA , SanderCR , AsherTE , et al. Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations. European Journal of Immunology2007;37(11):3089‐100. ">Beveridge 2007</a>). Thus, MVA85A was proposed primarily as a booster to people already vaccinated with BCG (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). Further studies have assessed MVA85A in other regimens including in combination with other viral vector vaccines (<a href="./references#CD012915-bbs2-0031" title="SheehanS , HarrisSA , SattiI , HokeyDA , DheenadhayalanV , StockdaleL , et al. A Phase I, Open‐Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS‐402 and MVA85A, Administered by Prime‐Boost Regime in BCG‐Vaccinated Healthy Adults. PLOS One2015;10(11):e0141687. ">Sheehan 2015</a>). </p> </section> <section id="CD012915-sec-0034"> <h3 class="title" id="CD012915-sec-0034">How the intervention might work</h3> <p>MVA85A is the first vaccine since 1968 to be tested in efficacy trials (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). It has been tried with a promise of prolonged antimycobacterial immunity in human UK trials (<a href="./references#CD012915-bbs2-0016" title="McShaneH , PathanAA , SanderCR , KeatingSM , GilbertSC , HuygenK , et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG‐primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine2004; Vol. 10:1240‐4. ">McShane 2004</a>), and in tuberculosis endemic areas (<a href="./references#CD012915-bbs2-0012" title="HawkridgeT , ScribaTJ , GelderbloemS , SmitE , TamerisM , MoyoM , et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. Journal of Infectious disease2008; Vol. 198, issue 4:544‐52. ">Hawkridge 2008</a>). The intention is that MVA85A would boost the immune response to tuberculosis above that which is afforded by vaccination with BCG (<a href="./references#CD012915-bbs2-0089" title="RoyA , EisenhutM , HarrisRJ , RodriguesLC , SridharS , HabermannS , et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta‐analysis. BMJ2014;349:g4643. [DOI: 10.1136/bmj.g4643] ">Roy 2014</a>). MVA85A is administered as a single intradermal dose in people who have already received BCG vaccine (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). Other routes have been studied in animal studies, such as intravenous administration (<a href="./references#CD012915-bbs2-0088" title="RomanoM , D'SouzaS , AdnetPY , LaaliR , JurionF , PalfietK , et al. Priming but not boosting with plasmid DNA encoding mycolyl‐transferase Ag85a from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. Tuberculosis H37Rv. Vaccine2006;24:3353‐64. ">Romano 2006</a>), and are being considered in humans (<a href="./references#CD012915-bbs2-0028" title="SattiI , MeyerJ , HarrisSA , ThomasZM , GriffithsK , AntrobusetRD , et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG‐vaccinated healthy adults: a phase 1, double‐blind, randomised controlled trial. Lancet Infectious diseases2014;14:939‐46. ">Satti 2014</a>). </p> <p>The researchers who developed the vaccine evaluated its effects in animals and conducted Phase 1 studies in humans. Early literature and reviews by the team noted the vaccine was safe and produced an immune response in several populations (<a href="./references#CD012915-bbs2-0016" title="McShaneH , PathanAA , SanderCR , KeatingSM , GilbertSC , HuygenK , et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG‐primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine2004; Vol. 10:1240‐4. ">McShane 2004</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>). </p> <p>One independent systematic review of the animal studies, carried out by some members of this Cochrane Review team, raised questions about whether these animal studies provided evidence of efficacy in the various animal models used (<a href="./references#CD012915-bbs2-0056" title="KashanguraR , SenaES , YoungT , GarnerP . Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. International Journal of Epidemiology2015;44(6):1970‐81. [DOI: 10.1093/ije/dyv142] ">Kashangura 2015</a>), when clinical and pathological endpoints were examined in a variety of animal models subjected to challenge studies. This has led to a debate about the reporting of animal studies, in particular the lack of published protocols so that the question being tackled in an animal study is made clear in advance (<a href="./references#CD012915-bbs2-0043" title="CohenD . Oxford TB vaccine study calls into question selective use of animal data. BMJ2018;360:j5845. ">Cohen 2018</a>). These studies administered BCG, BCG and MVA85A, or no vaccine. Afterwards, animals were exposed to tuberculosis challenge. Clearly progression to clinical trial is not solely based on evidence derived from preclinical efficacy studies, and MVA85A was evaluated in a number of trials in humans before proceeding to an efficacy study (<a href="./references#CD012915-bbs2-0062" title="McShaneH , HillA , HatherillM , TamerisM , SheaJ , GinsbergA . Helen McShane and colleagues reply to Deborah Cohen. BMJ2018;360:k236. ">McShane 2018</a>). However, preclinical studies remain an important component of the tuberculosis vaccine development paradigm (<a href="./references#CD012915-bbs2-0038" title="BarkerL , HesselL , WalkerB . Rational approach to selection and clinical development of TB vaccine candidates. Tuberculosis2012;92(Suppl 1):S25‐9. ">Barker 2012</a>; <a href="./references#CD012915-bbs2-0061" title="McShaneH , WilliamsA . A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis2014;94(2):105‐10. ">McShane 2014</a>). </p> <p>The systematic review of animal studies pointed out that there was one study in macaques where more monkeys required euthanasia in the MVA85A plus BCG vaccine group than the BCG control group (<a href="./references#CD012915-bbs2-0056" title="KashanguraR , SenaES , YoungT , GarnerP . Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. International Journal of Epidemiology2015;44(6):1970‐81. [DOI: 10.1093/ije/dyv142] ">Kashangura 2015</a>). This led to considerable controversy as to whether the publication of the results were delayed (<a href="./references#CD012915-bbs2-0043" title="CohenD . Oxford TB vaccine study calls into question selective use of animal data. BMJ2018;360:j5845. ">Cohen 2018</a>). The findings from this study could be the result of chance; or because the vaccine impaired functional immunity; or the result of a separate adverse effect. The vaccine development team then carried out a relatively large number of safety studies in humans; and, in their words, "none of the 14 trials of MVA85A in over 400 humans (the target species) before the infant efficacy trial showed a safety signal" (<a href="./references#CD012915-bbs2-0062" title="McShaneH , HillA , HatherillM , TamerisM , SheaJ , GinsbergA . Helen McShane and colleagues reply to Deborah Cohen. BMJ2018;360:k236. ">McShane 2018</a>). The standard approach for Cochrane Reviews within the Cochrane Infectious Diseases Group is to only summarize efficacy trials. However, as the primary concern of the studies included in this review was safety, we summarized the considerable number of Phase 1 studies that the researchers carried out to exclude severe adverse effects attributable to the vaccine in humans in this 'Background' section of the review. We searched registered clinical trial databases (ClinicalTrials.gov, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), Pan African Trials Registry, EU Clinical Trials Register) in June 2017 and summarized the Phase 1 studies identified in <a href="#CD012915-tbl-0002">Table 1</a>. We found 21 separate studies as registered (prospectively and retrospectively) dating from 2003 with the most recent studies scheduled to complete follow‐up in 2018. In addition, we found an existing narrative review of Phase 1 studies (<a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>), which summarized Phase 1 safety data relating to selected trials including unpublished data and compared this to selected trials in yellow fever and BCG. </p> <div class="table" id="CD012915-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of Phase 1 studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NCT trial number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Route</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and schedule details</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (age)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0064" title="NCT00423566 . A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis, antigen 85A, delivered intradermally by a needle injection in healthy volunteers. clinicaltrials.gov/ct2/show/NCT00423566 (first received 25 August 2017). ">NCT00423566</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002–2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 adults (18–45 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 trials (112 participants); combined in 1 report: no serious AE attributable to the vaccine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0016" title="McShaneH , PathanAA , SanderCR , KeatingSM , GilbertSC , HuygenK , et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG‐primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine2004; Vol. 10:1240‐4. ">McShane 2004</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0065" title="NCT00423839 . A phase I study of the safety and immunogenicity of MVA85A in healthy Gambian volunteers. clinicaltrials.gov/ct2/show/NCT00423839 (first received 25 August 2017). ">NCT00423839</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003–2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose, 2 doses</p> <p>(5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0007" title="BrookesRH , HillPC , OwiafePK , IbangaHB , JeffriesDJ , DonkorSA , et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLOS One2008;3(8):e2921. ">Brookes 2008</a>; <a href="./references#CD012915-bbs2-0054" title="IbangaHB , BrookesRH , HillPC , OwiafePK , FletcherHA , LienhardtC , et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis‐endemic countries: issues in study design. Lancet Infectious Diseases2006;6(8):522‐8. ">Ibanga 2006</a>; <a href="./references#CD012915-bbs2-0085" title="OwiafeP , HillP , IbangaHB , BrookesRH , McShaneH , SutherlandJS , et al. Differential cytokine levels in adults induced by a novel candidate TB boost vaccine, MVA85A‐according to previous BCG vaccination status. Journal of Vaccines &amp; Vaccination2012;3(7):158. ">Owiafe 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0067" title="NCT00427830 . A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis, antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have previously received BCG. clinicaltrials.gov/ct2/show/NCT00427830 (first received 25 August 2017). ">NCT00427830</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003–2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0016" title="McShaneH , PathanAA , SanderCR , KeatingSM , GilbertSC , HuygenK , et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG‐primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine2004; Vol. 10:1240‐4. ">McShane 2004</a>; <a href="./references#CD012915-bbs2-0024" title="PathanAA , MinassianAM , SanderCR , RowlandR , PorterDW , PoultonID , et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine2012;30(38):5616‐24. ">Pathan 2012</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a>; <a href="./references#CD012915-bbs2-0034" title="WhelanKT , PathanAA , SanderCR , FletcherHA , PoultonI , AlderNC , et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLOS One2009;10(11):e5934. ">Whelan 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0066" title="NCT00427453 . A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis, antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have received BCG immunisation 1 month previously. clinicaltrials.gov/ct2/show/NCT00427453 (first received 25 August 2017). ">NCT00427453</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003–2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0024" title="PathanAA , MinassianAM , SanderCR , RowlandR , PorterDW , PoultonID , et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine2012;30(38):5616‐24. ">Pathan 2012</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0068" title="NCT00456183 . Safety and immunogenicity of MVA85A in volunteers latently infected with TB. clinicaltrials.gov/ct2/show/NCT00456183 (first received 25 August 2017). ">NCT00456183</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A, (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 adults with latent tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AEs</p> <p>7 trials (112 participants; data combined in 1 report)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>; <a href="./references#CD012915-bbs2-0027" title="SanderCR , PathanAA , BeveridgeNE , PoultonI , MinassianA , AlderN , et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis‐infected individuals. American Journal of Respiratory and Critical Care Medicine2009;179:724‐33. ">Sander 2009</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0070" title="NCT00465465 . A study of 2 doses of a new TB vaccine, MVA85A, in healthy volunteers previously vaccinated with BCG. clinicaltrials.gov/ct2/show/NCT00465465 (first received 25 August 2017). ">NCT00465465</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (1 × 10<sup>8</sup> pfu for 12 participants, and 1 × 10<sup>7</sup> pfu for 12 participants) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0050" title="GriffithsKL , PathanAA , MinassianAM , SanderCR , BeveridgeNE , HillAV , et al. Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. PLOS One2011;6(8):e23463. ">Griffiths 2011</a>; <a href="./references#CD012915-bbs2-0060" title="MatsumiyaM , StylianouE , GriffithsK , LangZ , MeyerJ , HarrisSA , et al. Roles for Treg expansion and HMGB1 signaling through the TLR1‐2‐6 axis in determining the magnitude of the antigen‐specific immune response to MVA85A. PLOS One2013;8(7):e67922. ">Matsumiya 2013</a>; <a href="./references#CD012915-bbs2-0023" title="PathanAA , SanderCR , FletcherHA , PoultonI , AlderNC , BeveridgeNE , et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLOS One2007;2(10):e1052. ">Pathan 2007</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0069" title="NCT00460590 . Safety and immunogenicity of MVA85A, in healthy volunteers in Cape Town. clinicaltrials.gov/ct2/show/NCT00460590 (first received 25 August 2017). ">NCT00460590</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005–2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 adults and adolescents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0012" title="HawkridgeT , ScribaTJ , GelderbloemS , SmitE , TamerisM , MoyoM , et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. Journal of Infectious disease2008; Vol. 198, issue 4:544‐52. ">Hawkridge 2008</a>; <a href="./references#CD012915-bbs2-0029" title="ScribaTJ , TamerisM , MansoorN , ThomasZM , GriffithsK , AntrobusRD , et al. Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. European Journal of Immunology2010;40:279‐90. ">Scriba 2010</a>; <a href="./references#CD012915-bbs2-0032" title="TamerisM , GeldenhuysH , LuabeyaAK , SmitE , HughesJE , VermaakS , et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLOS One2014;9(2):e87340. ">Tameris 2014</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0071" title="NCT00480454 . Safety, immunogenicity, and impact of MVA85A, on the immunogenicity of the EPI vaccines. clinicaltrials.gov/ct2/show/NCT00480454 (first received 25 August 2017). ">NCT00480454</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006–2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A;</p> <p>1 dose MVA85A (2.5 × 10<sup>7</sup> pfu, 5 × 10<sup>7</sup> pfu) </p> <p>Groups</p> <p> <ul id="CD012915-list-0001"> <li> <p>EPI vaccines:</p> </li> <li> <p>MVA85A + EPI:</p> </li> <li> <p>MVA85A + EPI 1 week later</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 infants (4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE judged to be related to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0021" title="OdutolaAA , OwolabiOA , OwiafePK , McshaneH , OtaMO . A new TB vaccine, MVA85A, induces durable antigen‐specific responses 14 months after vaccination in African infants. Vaccine2012; Vol. 30:5591‐4. ">Odutola 2012</a>; <a href="./references#CD012915-bbs2-0022" title="OtaMO , OdutolaAA , OwiafePK , DonkorS , OwolabiOA , BrittainNJ , et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci. Transl. Med.2011; Vol. 3:88ra56. ">Ota 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0063" title="NCT00395720 . The safety and immunogenicity of a TB vaccine; MVA85A, in healthy volunteers who are infected with HIV. clinicaltrials.gov/ct2/show/NCT00395720 (first received 25 August 2017). ">NCT00395720</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006–2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup>pfu for 10 participants, and 1 × 10<sup>8</sup> pfu for 10 participants) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0018" title="Minassian , AM , RowlandR , BeveridgeNE , PoultonID , SattiI , HarrisS , et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV‐infected adults. BrItish Medical Journal2015; Vol. 1:e000223. ">Minassian 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0072" title="NCT00480558 . A study of MVA85A, in asymptomatic volunteers infected with TB, HIV or both. clinicaltrials.gov/ct2/show/NCT00480558 (first received 25 August 2017). ">NCT00480558</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup> pfu) </p> <p>4 groups with background of</p> <p> <ul id="CD012915-list-0002"> <li> <p>MTB</p> </li> <li> <p>HIV</p> </li> <li> <p>MTB + HIV</p> </li> <li> <p>HIV on ART</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 adults (18–50 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0030" title="ScribaTJ , TamerisM , SmitE , Van derMerwel , Jane HughesE , KadiraB , et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV‐ and/or Mycobacterium tuberculosis‐infected adults. American Journal of Respiratory and Critical Care Medicine2012;185(7):769‐78. ">Scriba 2012</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a>; <a href="./references#CD012915-bbs2-0032" title="TamerisM , GeldenhuysH , LuabeyaAK , SmitE , HughesJE , VermaakS , et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLOS One2014;9(2):e87340. ">Tameris 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0074" title="NCT00653770 . A phase I study to assess the safety and immunogenicity of tuberculosis (TB) vaccine candidates FP85A and MVA85A. clinicaltrials.gov/ct2/show/NCT00653770 (first received 25 August 2017). ">NCT00653770</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007–2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP85A, MVA85A (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0026" title="RowlandR , PathanAA , SattiI , PoultonID , MatsimuyaMM , WhitakerM , et al. Safety and immunogenicity of an FP9‐vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG‐vaccinated healthy adults: a phase I clinical trial. Human Vaccines and Immunotherapeutics2013;9(1):50‐62. ">Rowland 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0073" title="NCT00548444 . T‐cell turnover following vaccination with MVA85A. clinicaltrials.gov/ct2/show/NCT00548444 (first received 25 August 2017). ">NCT00548444</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007–2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose</p> <p>(1 × 10<sup>8</sup> pfu), administered as 2 injections (5 × 10<sup>7</sup> pfu each injection) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 trials (112 participants); data combined in 1 report: no serious AE attributable to the vaccine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Porter (unpublished data: source <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0075" title="NCT00731471 . A phase I study of a new tuberculosis (TB) vaccine, MVA85A, in healthy volunteers with HIV. clinicaltrials.gov/ct2/show/NCT00731471 (first received 25 August 2017). ">NCT00731471</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 2 doses (spaced by 6–12 months) (1 × 10<sup>8</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Senegal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0009" title="DieyeTN , NdiayeBP , DiengAB , FallM , BritainN , VermaakS , et al. Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART plus subjects. PLOS One2013;8(6):e67177. ">Dieye 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0077" title="NCT01181856 . Safety of tuberculosis vaccine, MVA85A, administered by the intramuscular route and the intradermal route. clinicaltrials.gov/ct2/show/NCT01181856 (first received 25 August 2017). ">NCT01181856</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> <p>IM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (1 × 10<sup>8</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0060" title="MatsumiyaM , StylianouE , GriffithsK , LangZ , MeyerJ , HarrisSA , et al. Roles for Treg expansion and HMGB1 signaling through the TLR1‐2‐6 axis in determining the magnitude of the antigen‐specific immune response to MVA85A. PLOS One2013;8(7):e67922. ">Matsumiya 2013</a>; <a href="./references#CD012915-bbs2-0017" title="Meyer , J , Harris , S.A , SattiI , PoultonID , PoyintzHC , TannerR , et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine2013; Vol. 31, issue 2013:1026‐33. ">Meyer 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0078" title="NCT01194180 . A BCG challenge model study to assess anti‐mycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A. clinicaltrials.gov/ct2/show/NCT01194180 (first received 25 August 2017). ">NCT01194180</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010–2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A, BCG;</p> <p>1 dose (1 × 10<sup>8</sup> pfu) </p> <p>Group A: BCG naive, no MVA85A<br/> Group B: BCG naive, MVA85A </p> <p>Group C: BCG vaccinated, no MVA85A</p> <p>Group D: BCG vaccinated, MVA85A.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 adults recruited; 48 completed study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>; <a href="./references#CD012915-bbs2-0052" title="HarrisSA , SattiI , MatsumiyaM , StockdaleL , ChomkaA , TannerR , et al. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. Clinical and Vaccine Immunology2014;21(7):1005‐11. ">Harris 2014b</a>; </p> <p><a href="./references#CD012915-bbs2-0060" title="MatsumiyaM , StylianouE , GriffithsK , LangZ , MeyerJ , HarrisSA , et al. Roles for Treg expansion and HMGB1 signaling through the TLR1‐2‐6 axis in determining the magnitude of the antigen‐specific immune response to MVA85A. PLOS One2013;8(7):e67922. ">Matsumiya 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0079" title="NCT01497769 . Safety of tuberculosis vaccine, MVA85A, administered by the aerosol route and the intradermal route. clinicaltrials.gov/ct2/show/NCT01497769 (first received 25 August 2017). ">NCT01497769</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol</p> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose: 1 × 10<sup>8</sup>, 1 × 10<sup>7</sup> pfu </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine related serious adverse effects.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0028" title="SattiI , MeyerJ , HarrisSA , ThomasZM , GriffithsK , AntrobusetRD , et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG‐vaccinated healthy adults: a phase 1, double‐blind, randomised controlled trial. Lancet Infectious diseases2014;14:939‐46. ">Satti 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0080" title="NCT01683773 . Safety study of tuberculosis vaccines AERAS‐402 and MVA85A. clinicaltrials.gov/ct2/show/NCT01683773 (first received 25 August 2017). ">NCT01683773</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012–2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AERAS‐402 MVA85A;</p> <p>Group A: 2 doses AERAS‐402 then MVA85A</p> <p>Group B: 1 dose AERAS‐402 then MVA85A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine related serious AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0031" title="SheehanS , HarrisSA , SattiI , HokeyDA , DheenadhayalanV , StockdaleL , et al. A Phase I, Open‐Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS‐402 and MVA85A, Administered by Prime‐Boost Regime in BCG‐Vaccinated Healthy Adults. PLOS One2015;10(11):e0141687. ">Sheehan 2015</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0082" title="NCT01879163 . Phase I trial evaluating safety and immunogenicity of MVA85A‐IMX313 compared to MVA85A in BCG vaccinated adults. clinicaltrials.gov/ct2/show/NCT01879163 (first received 25 August 2017). ">NCT01879163</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013–2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A IMX313;</p> <p>Group A: low‐dose MVA85A‐IMX313 (1 × 10<sup>7</sup> pfu) </p> <p>Group B: dose MVA85A‐IMX313 (5 × 10<sup>7</sup> pfu) </p> <p>Group C: MVA85A (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 BCG vaccinated adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0019" title="MinhinnickA , SattiI , HarrisS , WilkieM , SheehanS , StockdaleL , et al. A first‐in‐human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A‐IMX313, administered to BCG‐vaccinated adults. Vaccine Vol. 34, issue 2016:1412‐21. ">Minhinnick 2016</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0081" title="NCT01829490 . Safety study of ChAdOx185A vaccination with and without MVA85A boost in healthy adults. clinicaltrials.gov/show/NCT01829490 (first received 11 April 2013). ">NCT01829490</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013–2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A, ChAdOx1 85A;</p> <p>Group A: 1 dose ChAdOx1 85A</p> <p>Group B: 1 dose ChAdOx1 85A then MVA85A</p> <p>Group C: 2 doses ChAdOx1 85A then MVA85A (1 × 10<sup>8</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported yet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No publication</p> <p><a href="./references#CD012915-bbs2-0081" title="NCT01829490 . Safety study of ChAdOx185A vaccination with and without MVA85A boost in healthy adults. clinicaltrials.gov/show/NCT01829490 (first received 11 April 2013). ">NCT01829490</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0083" title="NCT01954563 . Study evaluating aerosol and intradermal administration of a candidate tuberculosis (TB) vaccine, MVA85A, as a way to increase immune response and avoid anti‐vector immunity. clinicaltrials.gov/ct2/show/NCT01954563 (first received 25 August 2017). ">NCT01954563</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol</p> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013–2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A;</p> <p>Group 1: aerosol then ID</p> <p>Group 2: ID then aerosol</p> <p>Group 3: ID then ID (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported yet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0058" title="ManjalyTZ , SattiI , WilkieM , HarrisS , RisteM , HamidiA , et al. A phase I trial evaluating aerosol administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti‐vector immunity. American Journal of Respiratory and Critical Care Medicine2016;193:A5487. ">Manjaly 2016</a> </p> <p>(conference abstract)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0084" title="NCT02532036 . MVA85A aerosol versus intramuscular vaccination in adults with latent Mycobacterium tuberculosis (M. tb) Infection. clinicaltrials.gov/show/NCT02532036 (first received 25 August 2015). ">NCT02532036</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol</p> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015–2018</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 × 10<sup>7</sup> pfu aerosol inhaled, </p> <p>5 × 10<sup>7</sup> aerosol and ID </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported yet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0084" title="NCT02532036 . MVA85A aerosol versus intramuscular vaccination in adults with latent Mycobacterium tuberculosis (M. tb) Infection. clinicaltrials.gov/show/NCT02532036 (first received 25 August 2015). ">NCT02532036</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>–ve: negative; +ve: positive; AE: adverse event; ART: antiretroviral therapy; BCG: bacillus Calmette‐Guérin; EPI: Expanded Programme on Immunization; ID: intradermal; IM: intramuscular; MTB: <i>Mycobacterium tuberculosis</i>; NR: not reported; pfu: plaque‐forming unit. </p> </div> </div> <p>The 21 studies included 712 participants investigated from 2002 with follow‐up expected to be completed by 2018. The studies covered a diverse population in the UK, South Africa, Senegal, and The Gambia with HIV‐positive and HIV‐negative people as well as infants, children, and adults. Intramuscular, intradermal, and aerosolized delivery routes were all investigated. The summary showed most of the adverse effects related to vaccination were mild and were contained locally to the injection site. There were very few serious adverse effects; erythema and mild pain were the most common adverse effects of the vaccine. </p> </section> <section id="CD012915-sec-0035"> <h3 class="title" id="CD012915-sec-0035">Why it is important to do this review</h3> <p>Summarizing the evidence to date will be useful to the public, scientists, and to others interested in innovation in tuberculosis as a case study from laboratory development to field testing. If critical appraisal and systematic review of this vaccine in humans shows no clear effect, this raises questions about any further testing. However, as of November 2017, there were ongoing studies looking at aerosolized delivery of the vaccine (<a href="./references#CD012915-bbs2-0083" title="NCT01954563 . Study evaluating aerosol and intradermal administration of a candidate tuberculosis (TB) vaccine, MVA85A, as a way to increase immune response and avoid anti‐vector immunity. clinicaltrials.gov/ct2/show/NCT01954563 (first received 25 August 2017). ">NCT01954563</a>; <a href="./references#CD012915-bbs2-0084" title="NCT02532036 . MVA85A aerosol versus intramuscular vaccination in adults with latent Mycobacterium tuberculosis (M. tb) Infection. clinicaltrials.gov/show/NCT02532036 (first received 25 August 2015). ">NCT02532036</a>). In 2017, studies were published that addressed the immunogenicity of the candidate tuberculosis vaccine MVA85A in <i>Schistosomiasis‐</i>infected teenagers (<a href="./references#CD012915-bbs2-0093" title="WajjaA , KizitoD , NassangaB , NalwogaA , KabagenyiJ , KimudaS , et al. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG‐vaccinated adolescents: an open‐label trial. PLOS Neglected Tropical Diseases2017;11(5):e0005440. ">Wajja 2017</a>), and a further efficacy study in HIV‐exposed infants (<a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012915-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012915-sec-0036"></div> <p>To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012915-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012915-sec-0037"></div> <section id="CD012915-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012915-sec-0039"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) that include measures of clinical efficacy (Phase 2 clinical trials). </p> </section> <section id="CD012915-sec-0040"> <h4 class="title">Types of participants</h4> <p>Any person regardless of age or HIV status.</p> </section> <section id="CD012915-sec-0041"> <h4 class="title">Types of interventions</h4> <section id="CD012915-sec-0042"> <h5 class="title">Intervention</h5> <p>MVA85A vaccine regardless of vaccination schedule, dosage, route, or formulation given with BCG. </p> </section> <section id="CD012915-sec-0043"> <h5 class="title">Control</h5> <p>BCG alone, or Candin® (<i>Candida albicans</i> skin test antigen). </p> </section> </section> <section id="CD012915-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD012915-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012915-list-0003"> <li> <p>Active tuberculosis, defined by:</p> <ul id="CD012915-list-0004"> <li> <p>clinical signs and symptoms plus confirmation by microscopy, culture, or Xpert® MTB/RIF (an automated nucleic‐acid amplification test); </p> </li> <li> <p>treatment commenced for tuberculosis.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD012915-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012915-list-0005"> <li> <p>Latent tuberculosis, diagnosed by IGRA or Mantoux without clinical or radiological evidence of active disease. </p> </li> </ul> </p> <section id="CD012915-sec-0047"> <h6 class="title">Adverse outcomes</h6> <p> <ul id="CD012915-list-0006"> <li> <p>Adverse effects of any severity, defined as "an adverse event for which the causal relation between the intervention and the event is at least a reasonable possibility" (<a href="./references#CD012915-bbs2-0057" title="LokeYK , PriceD , HerxheimerA . Chapter 14: Adverse effects. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Loke 2011</a>). </p> </li> <li> <p>Serious adverse effects, defined as an adverse event attributable to the intervention "leading to death, are life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, or result in persistent or significant disability or incapacity" (<a href="./references#CD012915-bbs2-0055" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Clinical safety data management: definitions and standards for expedited reporting E2A.1994. ICH harmonised tripartite guideline. Current Step 4 version dated 27 October 1994. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf (accessed 23 August 2017). ">ICH 1994</a>). </p> </li> <li> <p>Adverse events of any severity, defined as "any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment" (<a href="./references#CD012915-bbs2-0095" title="Uppsala Monitoring Centre. WHO adverse reaction terminology (WHO‐ART). www.who‐umc.org/vigibase/services/learn‐more‐about‐who‐art/ (accessed 23 August 2017). ">WHO‐ART 2008</a>). </p> </li> <li> <p>Abnormal haematological tests during the follow‐up period after being vaccinated.</p> </li> <li> <p>Abnormal biochemical tests during the follow‐up period after being vaccinated.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012915-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted the literature search up to the 10 May 2018 and identified potential studies regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD012915-sec-0049"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases using the search terms and strategy described in <a href="./appendices#CD012915-sec-0104">Appendix 1</a>: the Cochrane Infectious Diseases Group Specialized Register (10 May 2018); the Cochrane Central Register of Controlled Trials (CENTRAL, 2018, Issue 4, published in the Cochrane Library); MEDLINE (PubMed, 1966 to 10 May 2018); Embase (Ovid, 1947 to 10 May 2018); Science Citation Index‐Expanded, Social Sciences Citation index, conference proceedings (Web of Science, 1900 to 10 May 2018); and CINAHL (EBSCOHost (1982 to 10 May 2018). We also searched the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>), and ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov/ct2/home</a>), for trials in progress, up to 10 May 2018, using MVA85A, "modified vaccinia virus Ankara", Ag85A, "Antigen 85A", and tuberculosis OR tuberculosis as search terms. </p> </section> <section id="CD012915-sec-0050"> <h4 class="title">Searching other resources</h4> <p>We searched the proceedings and abstracts of the following tuberculosis conferences: Union World Conference on Lung Health, European Respiratory Society, and the International Conference of the American Thoracic Society (ATS), from 2012 to 2018. We also handsearched reference lists of relevant papers. </p> </section> </section> <section id="CD012915-sec-0051"> <h3 class="title" id="CD012915-sec-0051">Data collection and analysis</h3> <section id="CD012915-sec-0052"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened all abstracts retrieved by the search strategy above using predefined eligibility criteria designed and piloted by the review authors. We excluded clearly irrelevant studies. We searched for multiple publications using studies from the same data set. We retrieved full‐text copies for all trials thought to be potentially relevant. Two review authors (SoJ and SaJ) independently assessed all identified trials for inclusion in the review using the predefined inclusion criteria. </p> <p>We resolved any disagreements in assessment through discussion. In cases of unresolved differences, a third review author adjudicated. We kept records of the initial results and the changes after discussion. We also kept a list all studies excluded after full‐text assessment in the <a href="./references#CD012915-sec-0118" title="">Characteristics of excluded studies</a> table. We illustrated the study selection process in a PRISMA diagram (<a href="#CD012915-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012915-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012915-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012915-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>We designed and piloted data extraction forms. Two review authors independently performed data extraction. We gathered information from each included trial separately on trial characteristics. These included: </p> <p> <ul id="CD012915-list-0007"> <li> <p>study setting, design, study duration, population sample size, and power calculations;</p> </li> <li> <p>baseline characteristics of study population including age, sex, weight, prematurity, HIV, other comorbidity, whether breastfeeding, race, HIV status, antiretroviral therapy (ART), CD4 count, and viral load; </p> </li> <li> <p>intervention and control group vaccine dosages, routes of administration, and times of vaccination; </p> </li> <li> <p>time of outcome measure after administering MVA85A;</p> </li> <li> <p>duration of follow‐up, withdrawals from the study, and reasons for withdrawal.</p> </li> </ul> </p> <p>All outcomes were dichotomous, so we tabulated the numbers of participants who developed tuberculosis or an adverse event (n) with the total sample size number (N) in each comparison group. We documented the different definitions of outcomes in the trials for further consideration and only combined data from endpoints that were similar across studies. </p> </section> <section id="CD012915-sec-0054"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias for RCTs using the Cochrane 'Risk of bias' tool (<a href="./references#CD012915-bbs2-0053" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester (UK): Available from www.handbook.cochrane.org.. ">Higgins 2011</a>). Two review authors independently assessed studies for risk of bias. We resolved any disagreement through discussion and, where necessary, through consultation with a third review author. </p> <p>We assessed sequence generation (if predictable method used) and allocation concealment for selection bias and detection bias by looking at blinding methods. We also considered both the intention of blinding and the success of blinding for each outcome. If there was no description of the procedure, for example how randomization was done, we marked it as unclear. </p> <p>In addition, we examined the objectivity of outcome measures, use of intention‐to‐treat (ITT) analysis, loss to follow‐up, and selective outcome reporting to assess the risk of bias in included studies. We assessed whether outcome measures were specified a priori and whether the published endpoints matched those specified in study protocols. </p> <p>We assessed incomplete outcome data in each included trial to determine the proportion of missing results and whether it affected the results in terms of event risk and effect size. We assessed if reasons for missing data were related to adverse events or death from MVA85A and if missing data were balanced in the two experimental groups to have an overall decision on risk associated with incomplete outcome data. </p> <p>We assessed other dimensions to risk of bias, including conflicts of interest, large differences in baseline characteristics, and early cessation of the trial. </p> <p>We assessed the included trials for risk of bias of adverse events by examining if monitoring was active or passive; whether participants and outcome assessors were blinded; whether the outcome data reporting was complete; whether all participants were included; and whether data analysis was independent of pharmaceutical companies (<a href="#CD012915-tbl-0003">Table 2</a>; <a href="./references#CD012915-bbs2-0041" title="BukirwaH , UnnikrishnanB , KramerCV , SinclairD , NairS , TharyanP . Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD006404.pub2] ">Bukirwa 2014</a>). We also looked at the times when data were collected in comparison to when they were reported. All this information was included under overall study assessment of blinding, selective outcome reporting, incomplete outcome data, or other biases. </p> <div class="table" id="CD012915-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events risk of bias assessment methods</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Criterion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Participant‐reported symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was monitoring active or passive?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> <p>Passive</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified monitoring as 'active' when authors reviewed participants at set time points and enquired about symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was blinding for participants and outcome assessors adequate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> <p>Inadequate</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified blinding as 'adequate' when both participants and outcome assessors were blinded to the intervention group, and the methods of blinding (including use of a placebo) were described. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was outcome data reporting complete or incomplete?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete</p> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified outcome data reporting as 'complete' when data were presented for all the time points where it was collected. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Were all participants included in reporting?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We reported the percentage of randomized participants included in adverse event reporting.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was the analysis independent of study sponsor?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>No</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it was clearly stated that the sponsor had no input to the trial analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Laboratory tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of tests undertaken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We extracted the type and number of laboratory tests were taken.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Timing of tests: was number and timing of tests adequate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified the number and timing of tests as 'adequate,' when tests were taken at baseline, plus 2 other time points within the first week after treatment, plus the last day of the study. We classified the number of test taken as 'inadequate,' if either the laboratory controls in the first week or controls at 4 weeks were not performed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reporting of test results: was reporting of test results complete?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete</p> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified reporting as 'complete' when test results of all time points were reported. For the trials with inadequate number of tests taken, we considered completeness of reporting as inconsequential, and therefore did not record a judgement. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Independence of data analysis: was data analysis independent?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>No</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it is clearly stated that the sponsor had no input to the trial analysis. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Adapted from <a href="./references#CD012915-bbs2-0041" title="BukirwaH , UnnikrishnanB , KramerCV , SinclairD , NairS , TharyanP . Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD006404.pub2] ">Bukirwa 2014</a>. </p> </div> </div> </section> <section id="CD012915-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed all data using Review Manager 5 (<a href="./references#CD012915-bbs2-0087" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We pooled dichotomous data using risk ratios (RR) with their corresponding 95% confidence intervals (CI). When inappropriate due to a small number of events in each group, we presented the pooled data using risk difference (RD) with their 95% CI. </p> </section> <section id="CD012915-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>For included studies that had multiple intervention arms, we included data from these studies by splitting the control group so that participants were only included in the meta‐analysis once. </p> </section> <section id="CD012915-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>In our protocol, we anticipated that if the amount of incomplete outcome data was such that the trials were thought to be at a high risk of bias, we may have used imputation and perform sensitivity analyses to investigate the impact of these missing data. However, we identified no studies where missing data affected our ability to measure outcomes. Therefore, we used available‐case analysis, as planned in our protocol. </p> </section> <section id="CD012915-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed extracted data from included trials to find key differences in population groups, study setting, intervention and control groups, dosages and route of vaccine administration, or timing between BCG and boosting. We assessed degree of risk of bias, when and how the outcome was measured, and variation in treatment effects. </p> <p>We determined the level of heterogeneity by inspecting forest plots for overlapping CIs. We judged a Chi<sup>2</sup> P value significance level of 0.1 or less as likely heterogeneity. An I<sup>2</sup> statistic value of less than 40% was regarded as not showing any significant heterogeneity. </p> </section> <section id="CD012915-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>There was an insufficient number of trials included and so we were unable to assess for publication bias using funnel plots or Egger regression. </p> </section> <section id="CD012915-sec-0060"> <h4 class="title">Data synthesis</h4> <p>We used the fixed‐effect Mantel‐Haenszel model for meta‐analysis where there was little heterogeneity. The intention for meta‐analysis of adverse outcomes was limited to three to five of the most frequent adverse effects and all those that were considered to be serious. However, due to different methods of monitoring adverse effects that in turn lead to different results where meta‐analysis could not be performed, we gave a narrative report. </p> </section> <section id="CD012915-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to explore heterogeneity by: subgroup by children and adults; background prevalence of tuberculosis (or tuberculosis incidence in the control group); HIV status; and geographical location. However, there were not enough trials to explore such subgroups when we found high heterogeneity. </p> <p>We considered random‐effects meta‐analysis if subgroup analysis did not explain the heterogeneity. We applied the I<sup>2</sup> statistic according to guidance of: less than 40% as not significant heterogeneity; 30% to 60% representing moderate heterogeneity; 50% to 90% representing substantial heterogeneity; and 75% to 100% considerable heterogeneity (<a href="./references#CD012915-bbs2-0053" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester (UK): Available from www.handbook.cochrane.org.. ">Higgins 2011</a>). We regarded a Chi<sup>2</sup> P value significance level of 0.1 or less and an I<sup>2</sup> statistic greater than 40% as showing significant heterogeneity, in which case we either considered a random‐effects model or did not perform meta‐analysis. </p> </section> <section id="CD012915-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform sensitivity analysis for imputed data, risk of bias, or any other peculiarities between the trials identified during the review process. </p> <section id="CD012915-sec-0063"> <h5 class="title">Certainty of the evidence</h5> <p>We assessed the certainty of the evidence using the GRADE approach (<a href="./references#CD012915-bbs2-0090" title="SchünemannH , BrożekJ , GuyattG , OxmanA . GRADE handbook for grading quality of evidence and strength of recommendations. Available from guidelinedevelopment.org/handbookOctober 2013. ">Schünemann 2013</a>). We constructed a 'Summary of findings' table, which outlines the main review findings alongside the certainty of the evidence. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012915-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012915-sec-0064"></div> <section id="CD012915-sec-0065"> <h3 class="title">Description of studies</h3> <section id="CD012915-sec-0066"> <h4 class="title">Results of the search</h4> <p>We identified 153 records, with 152 records remaining after removing duplicates. We excluded 118 records based on title and abstract and assessed the full text of 34 articles. We excluded 28 full‐text articles. Six articles fulfilled the eligibility criteria and were included in the review. See <a href="#CD012915-fig-0001">Figure 1</a> for the flow diagram of inclusion and exclusion of studies in the review. </p> </section> <section id="CD012915-sec-0067"> <h4 class="title">Included studies</h4> <p>Six studies (3838 participants) that met our inclusion criteria reported findings from four Phase 2 clinical trials (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). <a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> and <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> presented data based on the <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> clinical trial. The six included studies are described in the <a href="./references#CD012915-sec-0117" title="">Characteristics of included studies</a> table. </p> <section id="CD012915-sec-0068"> <h5 class="title">Setting and time</h5> <p>All took place in South Africa involving rural and urban areas between 2008 and 2015, with one trial that took place at two sites: South Africa and Senegal (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>). </p> </section> <section id="CD012915-sec-0069"> <h5 class="title">Source of funding</h5> <p>Aeras sponsored five trials (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>; <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). The University of Oxford sponsored one trial (<a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>). The Wellcome Trust funded all the trials. Other funders were Oxford Emergent Tuberculosis Consortium (OETC) for <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> and <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>, the European and Developing Countries Clinical Trials Partnership and the Bill and Melinda Gates Foundation for <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>, the UK Medical Research Council for <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>, and the EuropeAID European Commission for <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>. <a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> and <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> conducted further follow‐up based on the participants enrolled in <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>, and mentioned that there was no specific additional funding for the analysis performed. </p> </section> <section id="CD012915-sec-0070"> <h5 class="title">Participants</h5> <p>Five trials included infants (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). One trial assessed the efficacy and safety of the vaccine in adults with HIV (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>). <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> and <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> recruited infants who were HIV‐negative, while <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> assessed the vaccine in newborns of HIV‐positive mothers. None of the trials reported other morbidities. In <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>, 412 (29.4%) participants in the intervention group and 268 (26.4%) participants in the control group were preterm. </p> </section> <section id="CD012915-sec-0071"> <h5 class="title">Interventions</h5> <section id="CD012915-sec-0072"> <h6 class="title">Intervention</h6> <p>All the infants in the intervention groups received a single dose of intradermal MVA85A. In the trial recruiting adults, the 324 adults allocated in the intervention group received a second dose (booster) of intradermal vaccine six months after the first dose (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>). The vaccine was given at a dose of 1 × 10<sup>8</sup> plaque‐forming units (pfu) in <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>, <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>, and <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>. <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> assessed three different doses of the vaccine by giving a dose of 2.5x10<sup>7</sup> pfu, 5x10<sup>7</sup> pfu and 1x 10<sup>8</sup> pfu to 36 participants in each of the three groups. All the infants in <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> and <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> received the BCG vaccine in the first four weeks of life, prior to receiving the MVA85A vaccine, as an inclusion criteria. <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> gave the MVA85A vaccine to the neonates in the first 96 hours of life, with no prior administration of BCG, and gave BCG at eight weeks of age only to HIV‐negative infants. <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> did not mention whether the adults they recruited received BCG. </p> </section> <section id="CD012915-sec-0073"> <h6 class="title">Comparator</h6> <p>Five trials gave Candida skin test antigen (Candin®) as a placebo, using the same route (intradermal) and schedule (one or two doses) as for the intervention group in each of the trial (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>; <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> gave the infants in the comparator group one dose of pneumococcal 7‐valent conjugate vaccine by the intramuscular route. </p> </section> </section> <section id="CD012915-sec-0074"> <h5 class="title">Outcomes</h5> <p>Three studies reported different endpoints as measures of tuberculosis disease (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). These are compared in <a href="#CD012915-tbl-0004">Table 3</a>. </p> <div class="table" id="CD012915-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Differences in tuberculosis endpoint assessment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint 3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of the following criteria.</p> <p> <ul id="CD012915-list-0008"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification <i>of M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (e.g. caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by an ophthalmologist.</p> </li> <li> <p>Miliary pattern on chest x‐ray in an HIV‐negative infant.</p> </li> <li> <p>Clinical diagnosis of TB meningitis (CSF protein concentrations &gt; 0.6 g/L and pleocytosis of &gt; 50 cells/μL with &gt; 50% mononuclear cells) with features of basal meningeal enhancement and hydrocephalus on head CT. </p> </li> <li> <p>Vertebral spondylosis.</p> </li> <li> <p>1 smear or histology specimen positive for auramine‐positive bacilli from a normally sterile body site. </p> </li> <li> <p>1 of each of the following:</p> <ul id="CD012915-list-0009"> <li> <p>evidence of mycobacterial infection defined as 2 acid‐fast positive smears (each from a separate collection) that were morphologically consistent with mycobacteria from either sputum or gastric aspirate that were not found to be non‐tuberculous mycobacteria bacteria on culture; QuantiFERON‐TB Gold In‐tube test conversion from negative to positive; or tuberculin skin test ≥15 mm and </p> </li> <li> <p>radiographic findings compatible with TB defined as ≥ 1 of the following factors identified independently by ≥ 2 of 3 paediatric radiologists serving on a masked review panel: calcified Ghon focus, pulmonary cavity, hilar or mediastinal adenopathy, pleural effusion, or airspace opacification and </p> </li> <li> <p>clinical manifestations compatible with TB defined as cough without improvement for &gt; 2 weeks; weight loss &gt; 10% of bodyweight for &gt; 2 months; or failure to thrive, defined as crossing &gt; 1 complete major centile band (&lt; 97th–90th, &lt; 90th–75th, &lt; 75th–50th, &lt; 50th–25th, &lt; 25th–10th, and &lt; 10th–3rd weight‐for‐age centiles) downward for &gt; 2 months. </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Included all infants who met endpoint 1 criteria; had marginally less stringent criteria to define TB infection and household exposure." </p> <p>Any of the following numerical categories.</p> <p> <ul id="CD012915-list-0010"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification <i>of M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (such as caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by an ophthalmologist.</p> </li> <li> <p>Miliary pattern on chest x‐ray in a HIV‐negative infant.</p> </li> <li> <p>Clinical diagnosis of TB meningitis (CSF protein &gt; 0.6 g/L and pleocytosis &gt; 50/mm<sup>3</sup> with mononuclear cell &gt; 50%) <b>or</b><sup>a</sup> features of basal meningeal enhancement and hydrocephalus on head CT. </p> </li> <li> <p>Vertebral spondylosis</p> </li> <li> <p>A single smear/histology specimen positive for auramine‐positive bacilli from a normally sterile body site. </p> </li> <li> <p>1 of each of the following:</p> <ul id="CD012915-list-0011"> <li> <p>evidence of mycobacterial infection defined as:</p> <ul id="CD012915-list-0012"> <li> <p>2 acid fast‐positive smears each from a separate collection morphologically consistent with mycobacteria from either sputum or gastric aspirate that are not found to be non‐tuberculous mycobacteria bacteria on culture, or </p> </li> <li> <p>QFT conversion from negative to positive, or</p> </li> <li> <p>Tuberculin skin test <b>≥ 10 mm</b>,<sup>a</sup> or </p> </li> <li> <p><b>household contact with AFB smear positive person</b><sup>a</sup> and </p> </li> </ul> </li> <li> <p>radiographic findings compatible with TB defined as ≥ 1 of the following identified independently by at least 2 out of 3 paediatric radiologists serving on a blinded review panel: calcified Ghon focus, pulmonary cavity, hilar/mediastinal adenopathy, pleural effusion, or airspace opacification and </p> </li> <li> <p>clinical manifestations compatible with TB defined as either</p> <ul id="CD012915-list-0013"> <li> <p>cough without improvement for &gt; 2 weeks, or</p> </li> <li> <p>weight loss ≥ 10% of bodyweight for ≥ 2 months, or</p> </li> <li> <p>failure to thrive (crossing ≥ 1 entire major centile band downward) for ≥ 2 months, where the major centile bands are defined as &lt; 97th–90th, &lt; 90th–75th, &lt; 75th–50th, &lt; 50th–25th, &lt; 25th–10th, and &lt; 10th–3rd weight‐for‐age centiles. </p> </li> </ul> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants placed on treatment for TB by a health professional with the intent of treating TB regardless of whether they have met the other efficacy endpoints. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revised endpoint 1 from <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> that removed QFT conversion from the diagnostic criteria to avoid bias towards association with QFT status. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same definition as for <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of the following numerical categories.</p> <p> <ul id="CD012915-list-0014"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification of <i>M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (such as caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by ophthalmologist.</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of the following numerical categories:</p> <p> <ul id="CD012915-list-0015"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification of <i>M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (such as caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by ophthalmologist.</p> </li> <li> <p>A single smear/histology specimen positive for AFB from a normally sterile body site.</p> </li> <li> <p>2 acid‐fast smears positive each from a separate collection morphologically consistent with mycobacteria from either pulmonary or gastric sampling that are not found to be non‐tuberculous mycobacteria bacteria on culture, and ≥ 1 of the following: </p> <ul id="CD012915-list-0016"> <li> <p>a compatible radiographic feature: airspace opacification, cavity, hilar or mediastinal adenopathy, or pleural effusion; </p> </li> <li> <p>a compatible clinical feature, i.e. &gt; 2 weeks of fever, night sweats, anorexia, cough, or weight loss (≥ 5 kg by history or noticeable change in clothing fit); or ≥ 1 episodes of haemoptysis. </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same definition as for <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes not specified in the methods section.</p> <p>In results, authors specified that 8 participants were diagnosed as TB:</p> <p>"of whom one was M.tb [<i>Mycobacterium tuberculosis]</i> culture positive and 7 were diagnosed on clinical/ radiographic grounds and TB contact history. Two of the TB cases were QFT positive." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AFB: acid‐fast bacilli; CSF: cerebrospinal fluid; CT: computerized tomography; QFT: quantiFERON; TB: tuberculosis.<br/> <sup>a</sup>In <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>, endpoint 2: criteria in bold indicate where different from endpoint 1. </p> </div> </div> <p>All the included studies reported data on latent tuberculosis (or tuberculosis infection) to assess either efficacy or safety outcomes. Four trials looked at safety outcomes, including adverse effects of any severity, serious adverse effects, and adverse events of any severity (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> collected data on biochemical or haematological blood test findings but did not report this element of their primary outcome. <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> collected data on blood tests but did not report disaggregated findings. Only <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> and <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> reported on blood test data collected. </p> </section> <section id="CD012915-sec-0075"> <h5 class="title">Length and method of follow‐up</h5> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> followed up participants for 24 weeks, <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> for 52 weeks, <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> for at least six months after the last participant was enrolled, and <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> for up to 39 months. <a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> was an observational follow‐up study of the participants enrolled in <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>; authors analysed the data collected at day 336 after the intervention and at the end of the study, which ranged from six to 24 months after day 336. <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> followed the participants recruited in <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> for a median of five years. </p> <p>Investigators of five studies used diary cards to record adverse events during the seven days following vaccination (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>; <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>); <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> did not mention this. Researchers performed blood investigations at several intervals in all trials, to detect adverse events and to assess immunogenicity. <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> and <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> performed active follow‐up every three months to identify signs, symptoms, or exposure to tuberculosis that merited further investigation, while this was done at irregular but planned intervals in <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> and <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>. The long‐term follow‐up study was based on passive surveillance based on the electronic tuberculosis register database (<a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>). </p> </section> </section> <section id="CD012915-sec-0076"> <h4 class="title">Excluded studies</h4> <p>We excluded 28 studies from the review, with the reasons for exclusion listed in the <a href="./references#CD012915-sec-0118" title="">Characteristics of excluded studies</a> table. </p> <section id="CD012915-sec-0077"> <h5 class="title">Studies awaiting classification</h5> <p>We did not identify any studies that are awaiting classification.</p> </section> <section id="CD012915-sec-0078"> <h5 class="title">Ongoing studies</h5> <p>We did not identify any ongoing studies.</p> </section> </section> </section> <section id="CD012915-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD012915-sec-0117" title="">Characteristics of included studies</a> table for the assessment of the risk of bias for each included study. See <a href="#CD012915-fig-0002">Figure 2</a> and <a href="#CD012915-fig-0003">Figure 3</a> for the risk of bias summaries. </p> <div class="figure" id="CD012915-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012915-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012915-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012915-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012915-sec-0080"> <h4 class="title">Allocation</h4> <p>Five trials were at low risk of selection bias (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>; <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). They reported adequate sequence generation and methods of allocation concealment. <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> used systematic allocation at a 3:1 ratio allowing predictability of the sequence (high risk of bias). </p> </section> <section id="CD012915-sec-0081"> <h4 class="title">Blinding</h4> <p>Three studies had adequate blinding of participants, study personnel, laboratory assessors, and clinical assessors and were at low risk for performance and detection bias in all domains (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). Five studies reported blinding of participants and study personnel (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>; <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>, an open‐label trial with different routes of administration for placebo and vaccine, had low risk of detection bias for laboratory assessors as outcomes were objective and high risk of detection bias for subjective assessments by clinicians. Two studies were at unclear risk of detection bias for laboratory assessors and clinicians (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>). <a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> did not provide any details on blinding, while <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> reported on post‐trial data and had no information on how data was collected from registers. </p> </section> <section id="CD012915-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>Four trials reported details of all randomized participants (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). Only a few participants randomized were not included in the analysis, without resulting in a disbalance between the intervention and control groups. Indeed, three participants were randomized in the control group in <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>, but not included in the efficacy analysis (two of them were not included either in the safety analysis), while five participants were randomized (four in the intervention group and one in the control group), but not included in the efficacy analysis in <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>. As a result we considered these studies at low risk of attrition bias. There were no details of how many of each group came from the 119 participants excluded from <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> for analysis in <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>. <a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> and <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> had an unclear risk of attrition bias as these were follow‐up studies from <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>, and there were unclear discrepancies with those reported previously. </p> </section> <section id="CD012915-sec-0083"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> was prospectively registered and appeared free of selective outcome reporting as ascertained from data in trial registers and reports of trials. We also judged <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> at low risk of reporting bias, with all the outcomes reported in their methods section presented in the results. </p> <p>Four studies were at unclear risk of bias due to selective reporting (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>; <a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a>; <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). There were multiple instances where predefined endpoints were poorly defined or were deviated from in the final reported results as laid out in <a href="#CD012915-tbl-0005">Table 4</a>. </p> <div class="table" id="CD012915-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Differences between details of studies published prior to commencement and reported outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Protocol</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Published findings</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Differences between protocol and published findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stated outcomes published prior to commencement of trial that differ to published outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement of outcome as stated a priori</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement of outcome as stated in published findings</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No protocol published.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No protocol published (extended post‐trial follow‐up of <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: blood tests <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Percentage of participants with adverse events" AEs measured up to day 28</p> <p>SAEs measured up to 6 months.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Phlebotomy for routine haematological and biochemical analysis was done at screening, before booster vaccination, and on days 7 and 28 after each vaccination." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Routine haematological and biochemical test results did not differ between study groups (data not shown)." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematological and biochemical blood tests not outlined as a measure of safety in the study protocol. Blood test findings reported unclearly. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicaltrials.gov – local, regional, and systemic AEs and SAEs which would be reported as cumulative 12‐month incidences. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Infants followed for safety end points at weeks 1, 4, 6, and 8 after MVA85A/control vaccination and thereafter, at weeks 9, 12, and 16 (corresponding to weeks 1, 4, and 8 following delayed BCG vaccination at 8 weeks of age), and at week 52." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported total events for AEs per group after MVA85A and before BCG and for whole follow‐up period. Data including for laboratory AEs were not disaggregated as prespecified. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data including for laboratory AEs were not disaggregated as prespecified.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Safety<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local and systemic AEs for the first week.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diary cards</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local and systemic AEs reported on ≥ 1 day of the first 7 days after MVA85A vaccination.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood tests (days 7, 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical and haematological tests (days 7, 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported number and percentages of participants with abnormal results and reported that, "all except one patient that had elevated liver enzymes remained unresolved by day 28." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ESAT‐6/CFP‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants converted – suggestive of TB infection but seemed to be reported as safety data not efficacy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety profile – AEs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs measured up to day 28</p> <p>SAEs measured throughout follow‐up.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Collected data on solicited and unsolicited local and systemic AEs.</p> <p>Active surveillance for SAEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs broken down by type of event and reported in supplementary material. Only local events at the injection site were considered to be related to the vaccine. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Causal relationship with AEs other than local injection site reactions was not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety profile – blood tests<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testing up to 28 days postvaccination.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Peripheral blood for routine haematological and biochemical tests was taken at screening and on day 7 and day 28 after vaccination in an initial safety cohort of at least 330 infants." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy of MVA85A<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Using an endpoint derived from epidemiological cohort surveys in BCG vaccinated infants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported – simply stated clinical endpoints 'developed.'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Composite clinical endpoints 1, 2, 3 (see <a href="#CD012915-tbl-0004">Table 3</a>) </p> <p>Microbiologically confirmed cases reported in appendix.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The "primary efficacy endpoint" was measured using an endpoint not derived from cohort studies. </p> <p>The endpoint definition differed from all other implied or reported ways of measuring efficacy in the other studies. The point estimate showed clinically significant benefit for endpoint 1 (no benefit seen at the 95% confidence level). This endpoint was reported as the main efficacy finding. All other point estimates show no clinically significant benefit or harm. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse events; BCG: bacillus Calmette‐Guérin; ESAT‐6/CFP‐10: early secretory antigenic‐6/culture filtrate protein‐10; SAE: severe adverse events; TB: tuberculosis.<br/> <sup>a</sup>Primary outcomes as outlined in study protocols.<br/> <sup>b</sup>Secondary outcomes as outlined in study protocols. </p> </div> </div> <p>Description of <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> published prior to commencement of the trial (<a href="./references#CD012915-bbs2-0076" title="NCT00953927 . A study of MVA85A in healthy infants. clinicaltrials.gov/ct2/show/NCT00953927 (first received 25 August 2017). ">NCT00953927</a>) stated that the authors intended to report endpoints of clinical disease based on "observational cohort studies." This was subsequently changed following the publication of the trial in October 2013 to include "clinically‐derived tuberculosis diagnostic criteria." The main trial reports adapting the primary elements proposed in a consensus statement (<a href="./references#CD012915-bbs2-0049" title="GrahamSM , AhmedT , AmanullahF , BrowningR , CardenasV , CasenghiM , et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. Journal of Infectious Diseases2012;205(2):S199‐208. ">Graham 2012</a>). There was no record of the change in approach from empirically derived endpoints to endpoints developed by the investigators in the study protocol. </p> <p>Tameris and colleagues reported on three outcomes with complex definitions (<a href="#CD012915-tbl-0004">Table 3</a>). </p> <p> <ul id="CD012915-list-0017"> <li> <p>Endpoint one, described as "primary efficacy endpoint," comprising nine criteria, which included a binary measure of quantiFERON conversion. </p> </li> <li> <p>Endpoint two, described as "exploratory efficacy endpoint," comprising nine criteria.</p> </li> <li> <p>Endpoint three, described as "exploratory efficacy endpoint," which was defined as "all participants placed on treatment for tuberculosis." </p> </li> </ul> </p> <p>The difference between endpoints one and two, which varied in the direction of the point estimate of the effect, was 5 mm on a tuberculin skin test or household contact with acid‐fast bacilli (AFB) smear‐positive person (<a href="#CD012915-tbl-0004">Table 3</a>). The process of defining these three endpoints was unexplained, and it is unclear why these specific definitions were used. These endpoint definitions were only used in this trial and not in subsequent studies. </p> <p>In a subsequent critique, Behr and colleagues noted that the outcomes reported in the trial did not include the simple measure of a positive microbiological endpoint (<a href="./references#CD012915-bbs2-0039" title="BehrMA , SchwartzmanK , PaiM . Tuberculosis vaccine trials. Lancet2013;381(9885):2252‐3. ">Behr 2013</a>). The endpoint used in the abstract was endpoint one, which authors have settled as primary efficacy outcome, while endpoints two and three were reported as exploratory outcomes. The complexity of the definitions and the analysis in Behr's paper pointed to the risk of selective reporting. This may not have been intentional, but arose with post‐hoc approaches with different approaches to expressing the results, but could be excluded if outcomes were precisely and clearly defined a priori. The only information publicly available prior to the trial commencing were broad descriptions of the outcome. Hence for selective reporting the classification was unclear. </p> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> was at unclear risk of reporting bias as this was a nested observational study and there was no prespecified study protocol. <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> was at unclear risk of reporting bias as the authors commented that there were no differences between biological and haematological tests; however, no data or how these data were analysed to come to this conclusion were reported. </p> </section> <section id="CD012915-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>We considered that the risk of other potential biases was unclear in all included studies. We were concerned as a number of the authors were involved in the private company manufacturing the vaccine or were patent holders for MVA85A. In these circumstances, it would be good practice for this to be declared in the publication. Only one study declared no conflicts in relation to patent holding (<a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>). </p> <p>Two trials reported a role of funders in design, data analysis, and manuscript writing (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>), and one study had employees of the funder involved in manuscript writing (<a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a>). <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> calculated incident tuberculosis cases from day 28 after vaccination versus from day 0 in <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>. This was likely to be due to the risk of pre‐existing undiagnosed tuberculosis being inappropriately counted as developing following the intervention. If participants are not followed from the start of the intervention then a period of follow‐up has been excluded, and participants who experienced the outcome soon after intervention will be missing from analyses. We considered this to be of unclear risk of bias as it is unclear if this impacted on outcomes. </p> <section id="CD012915-sec-0085"> <h5 class="title">Adverse events</h5> <p>For adverse events, we conducted additional assessments on adequacy of safety monitoring and completeness of reporting for participant‐reported outcomes and laboratory tests taken (<a href="#CD012915-tbl-0006">Table 5</a>). Four trials reported on safety outcomes (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). Monitoring of participant‐reported outcomes was active in all trials and blinding was adequate in two trials (<a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). All trials reported specified timing of data collection but only one study reported under some of the days (<a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>). None of the trials completely reported outcomes on prespecified time points including for laboratory results. All trials reported all participants who received intervention per‐protocol. Timing of taking laboratory tests was inadequate in <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> and <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> as there was no clear indication of tests being taken at the end of the study. </p> <div class="table" id="CD012915-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of monitoring and reporting of adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Participant reported adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Outcome data reporting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Laboratory tests</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Monitoring active or passive</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants or outcome assessors</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Times data collected</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Times data reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete/not complete</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage of participants reported on</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis independent of study sponsor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of tests taken</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Timing of tests and adequacy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete reporting of test results</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Independence of data analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 min, D 2, 7, 28, 84, and 168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 7, 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemistry and haematology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inconsequential</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 7, 28, and 84 after boost 3 monthly until end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematology, chemistry, virological markers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, D 7 and 28, throughout up to D 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemistry and haematology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 1, 4, 6, 8, 16, and 52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>D: day; min: minute; NR: not reported.</p> </div> </div> </section> </section> </section> <section id="CD012915-sec-0086"> <h3 class="title" id="CD012915-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD012915-tbl-0001"><b>Summary of findings for the main comparison</b> MVA85A compared to placebo for preventing tuberculosis</a> </p> <p>See <a href="./full#CD012915-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD012915-sec-0087"> <h4 class="title">Active tuberculosis</h4> <p>Studies varies in the way they defined active tuberculosis (see section "description of studies" (<a href="#CD012915-tbl-0004">Table 3</a>)). <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> and <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> reported hierarchical endpoints including microbiologically confirmed tuberculosis, composite clinical definitions, and participants starting on tuberculosis treatment, with no significant effect consistently seen across endpoints (<a href="./references#CD012915-fig-0016" title="">Analysis 2.1</a>; <a href="./references#CD012915-fig-0017" title="">Analysis 2.2</a>; <a href="#CD012915-tbl-0004">Table 3</a>; <a href="#CD012915-tbl-0007">Table 6</a>). </p> <div class="table" id="CD012915-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Results of the different endpoints of active tuberculosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Active TB </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. "><b>Tameris 2013</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. "><b>Andrews 2017</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] "><b>Bunyasi 2017</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. "><b>Ndiaye 2015</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] "><b>Scriba 2011</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] "><b>Nemes 2018</b> </a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint 1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/1399 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/1395 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>58/2797 (2.1%) with NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/320 (1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/325 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/123 (4.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/125 (2.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint 2<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/1399 (3.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/1395 (3.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/320 (1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/325 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint 3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196/1399 (14.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177/1395</p> <p>(12.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3/100 pyo</p> <p>(95% CI 2.9 to 3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0/100 pyo (95% CI 2.6 to 3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/320 (2.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/325 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; N/A: not applicable; NDD: no disaggregated data; pyo: person‐years of observation; TB: tuberculosis.<br/> <sup>a</sup>See <a href="#CD012915-tbl-0004">Table 3</a> for description of endpoints. </p> </div> </div> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> reported three endpoints in their main manuscript, with endpoint one described as their primary efficacy endpoint (RR 0.82, 95% CI 0.52 to 1.30, point estimate favouring MVA85A). A fourth endpoint was described in the supplementary material, taking into account the microbiologically confirmed cases of tuberculosis. Other outcomes (endpoint two, endpoint three, and endpoint four of microbiologically confirmed cases) were not statistically different, although their point estimate favoured placebo (endpoint two: RR 1.05, 95% CI 0.73 to 1.53; endpoint 3: RR 1.10, 95% CI 0.91 to 1.33; endpoint four (microbiologically confirmed): RR 1.10, 95% CI 0.60 to 2.00; <a href="./references#CD012915-fig-0016" title="">Analysis 2.1</a>; <a href="#CD012915-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD012915-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Comparison of endpoints, outcome: 2.1 Tameris 2013: incidence of tuberculosis according to post‐hoc endpoints." data-id="CD012915-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Comparison of endpoints, outcome: 2.1 Tameris 2013: incidence of tuberculosis according to post‐hoc endpoints. </p> </div> </div> </div> <p>Two studies reported no effect of MVA85A on cases of active tuberculosis confirmed by culture or Xpert® MTB/RIF (RR 0.97, 95% CI 0.58 to 1.62; 3439 participants, two trials) (<a href="./references#CD012915-fig-0008" title="">Analysis 1.1</a>; <a href="#CD012915-fig-0005">Figure 5</a>; <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). </p> <div class="figure" id="CD012915-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 MVA85A Vs Placebo, outcome: 1.1 Tuberculosis confirmed by culture or Xpert® MTB/RIF longest reported follow‐up." data-id="CD012915-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 MVA85A Vs Placebo, outcome: 1.1 Tuberculosis confirmed by culture or Xpert® MTB/RIF longest reported follow‐up. </p> </div> </div> </div> <p>Three studies (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>) reported no effect of MVA85A on cases of active tuberculosis when considering patients started on tuberculosis treatment (RR 1.10, 95% CI 0.92 to 1.33; 3687 participants, 3 trials; <a href="./references#CD012915-fig-0009" title="">Analysis 1.2</a>; <a href="#CD012915-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD012915-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.2 Active tuberculosis: started on tuberculosis treatment." data-id="CD012915-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.2 Active tuberculosis: started on tuberculosis treatment. </p> </div> </div> </div> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> reported active tuberculosis as defined by participants starting tuberculosis treatment. One participant in this trial was diagnosed by culture; however, the authors did not report what intervention this participant received. </p> </section> <section id="CD012915-sec-0088"> <h4 class="title">Latent tuberculosis</h4> <p>Four studies reported no effect of MVA85A on cases of latent tuberculosis (RR 1.01, 95% CI 0.85 to 1.21; 3831 participants, four trials; <a href="./references#CD012915-fig-0010" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> was underpowered and not designed to detect measures of efficacy. However, they reported latent tuberculosis, presumably as a measure of safety, as this outcome was poorly defined a priori. </p> </section> <section id="CD012915-sec-0089"> <h4 class="title">Adverse effects</h4> <p>Four studies reported effects of any severity (<a href="#CD012915-tbl-0008">Table 7</a>). We presented the effect of the estimates for adverse effects of any severity with disaggregated (<a href="./references#CD012915-fig-0011" title="">Analysis 1.4</a>; <a href="#CD012915-fig-0007">Figure 7</a>) and aggregated data (<a href="./references#CD012915-fig-0012" title="">Analysis 1.5</a>) to provide detailed information as provided by the study authors. However, we did not perform meta‐analysis of the estimates due to high heterogeneity. Local reactions of the skin at the injection site was the most common adverse effect associated with the vaccine MVA85A, this was reported in three studies, with the three studies showing direction towards more adverse effects in the intervention group (3187 participants; <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a>; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). However, only one study reported systemic symptoms defined as fever, lethargy, malaise, and vomiting (144 participants; <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>). Therefore, we chose to report adverse effects of any severity disaggregated by local reactions of the skin and systemic symptoms in our <a href="./full#CD012915-tbl-0001">summary of findings Table for the main comparison</a> as different amount of information is provided for each group (<a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a>). </p> <div class="figure" id="CD012915-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.4 Adverse effects of any severity." data-id="CD012915-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.4 Adverse effects of any severity. </p> </div> </div> </div> <div class="table" id="CD012915-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects of the MVA85A vaccine</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Breakdown</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Author conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with ≥ 1 event caused by the intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with ≥ 1 event caused by the control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Detailed AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solicited AEs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Solicited adverse events were more common in MVA85A group and most were local injection site reactions." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not detailed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Infants in MVA85A arm were more likely to experience an AE than in control arm. Injection site reactions were more frequent in MVA85A recipients and mild." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>106<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>108<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injection site<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>"Desquamation significantly increased with greater vaccine dose."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tactile fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Documented fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated liver enzyme levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased white cell count</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local 1251<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local 628<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not detailed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event; N/A: not applicable.<br/> <sup>a</sup>Included injection reactions, mild influenza‐like symptoms, and regional lymphadenopathy.<br/> <sup>b</sup>Authors of the study reported 105 participants with at least one adverse effect in the vaccine group and 30 participants in the placebo group, where causal relationship was defined as definite.<br/> <sup>c</sup>Aggregated between three groups receiving different doses.<br/> <sup>d</sup>Included desquamation (scaling), pain, redness, and swelling.<br/> <sup>e</sup>Authors of the study reported local and systemic adverse events. Authors specified in their protocol that, "Solicited adverse events of local injection site reactions will be considered causally related to study vaccine (adverse reaction)." Therefore, we reported such adverse events as adverse effects. Causal relationship with other adverse events was not reported. </p> </div> </div> <p>Three studies reported no increase in the risk of experiencing a serious adverse effect attributable to MVA85A (3692 participants; <a href="./references#CD012915-fig-0013" title="">Analysis 1.6</a>). <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> reported serious adverse events and specified that none of them were related to the investigational product. Therefore, we classified this as no serious adverse effects following the definition of our review. </p> </section> <section id="CD012915-sec-0090"> <h4 class="title">Adverse events of any severity</h4> <p>Four studies reported a small increase in the risk of experiencing an adverse event of any severity following vaccination with MVA85A (RR 1.05, 95% CI 1.02 to 1.08; 3836 participants; <a href="./references#CD012915-fig-0014" title="">Analysis 1.7</a>; <a href="#CD012915-tbl-0009">Table 8</a>). Adverse effects related to the vaccine and adverse events not attributed to the vaccine were conflated in the largest trial. No disaggregated data were available. </p> <div class="table" id="CD012915-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events summary table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Adverse events of any severity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>1120/1399 (80.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1059/1396 (75.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>321/324</p> <p>(99.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312/325</p> <p>(96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 × 10<sup>7</sup> </p> <p>pfu = 35 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 × 10<sup>7</sup> </p> <p>pfu = 70 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 × 10<sup>8</sup> </p> <p>pfu = 135 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1/36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Mild 122/123</p> <p>(99.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121/125</p> <p>(96.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Moderate 62/123</p> <p>(50.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54/125</p> <p>(3.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Severe 11/123</p> <p>(8.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/125</p> <p>(11.2%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: not reported; pfu: plaque‐forming unit.</p> </div> </div> </section> <section id="CD012915-sec-0091"> <h4 class="title">Abnormal haematological and biochemical tests</h4> <p>Three studies reported abnormal haematological or biochemical laboratory tests. The percentage of those with elevated liver enzymes ranged from 2.8% to 25% in the three different groups reported in <a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> and there was a dose–response effect of MVA85A. However, none of the doses showed a significant increase at a 95% CI. <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> reported that routine haematological and biochemical test results did not differ between study groups but disaggregated data were not reported. <a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> reported no difference between groups in the percentage of people with abnormal biochemical tests (11.4% versus 10.4%), but disaggregated data were not reported. The largest study performed haematological and biochemical tests but did not report data (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). We summarized the report and findings of abnormal haematological and biochemical tests in <a href="#CD012915-tbl-0010">Table 9</a>, and presented the effect of estimate for abnormal biochemical tests only (<a href="./references#CD012915-fig-0015" title="">Analysis 1.8</a>), as only one study reported disaggregated data for abnormal haematological tests. </p> <div class="table" id="CD012915-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Abnormal haematological and biochemical tests</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Haematological blood tests</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Biochemical blood tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0/108<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1/36<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 × 10<sup>7</sup> </p> <p>pfu = 35 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 × 10<sup>7</sup> </p> <p>pfu = 70 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 × 10<sup>8</sup> </p> <p>pfu = 135 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4/36</p> <p>(11%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/36</p> <p>(2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/36</p> <p>(8.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/36</p> <p>(25%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>14/123 (11.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/125</p> <p>(10.4%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: not reported; pfu: plaque‐forming unit.<br/> <sup>a</sup>Authors stated that routine haematological and biochemical test results did not differ between study groups but did not present data.<br/> <sup>b</sup>One participant had increased white cell count concurrently with an increase in alanine aminotransferase during an episode of gastroenteritis. Authors did not describe any other case of abnormal haematological test in the rest of the participant, although it was not stated explicitly. </p> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012915-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012915-sec-0092"></div> <section id="CD012915-sec-0093"> <h3 class="title" id="CD012915-sec-0093">Summary of main results</h3> <p>Vaccinating people with MVA85A in addition to BCG:</p> <p> <ul id="CD012915-list-0018"> <li> <p>probably makes little or no difference to the risk of developing active tuberculosis (moderate‐certainty evidence); </p> </li> <li> <p>probably makes little or no difference to the risk of needing to start tuberculosis treatment (moderate‐certainty evidence); </p> </li> <li> <p>probably does not have an important effect on the risk of developing latent tuberculosis (moderate‐certainty evidence); </p> </li> <li> <p>does not cause life‐threatening serious adverse effects (high‐certainty evidence);</p> </li> <li> <p>probably increases the risk of having an adverse reaction related to vaccination at the site of the injection (moderate‐certainty evidence); </p> </li> <li> <p>may not be associated with an increase in systemic adverse effects related to vaccination (low‐certainty evidence). </p> </li> </ul> </p> <p>Vaccination with MVA85A alone slightly increases the risk of having an adverse event (high‐certainty evidence). </p> </section> <section id="CD012915-sec-0094"> <h3 class="title" id="CD012915-sec-0094">Overall completeness and applicability of evidence</h3> <p>This review included trials from two countries in Africa. No studies that measured efficacy of the MVA85A vaccine have been carried out elsewhere. The review included studies on HIV‐positive adults, HIV‐negative infants, and infants exposed to HIV. It would be reasonable to generalize the results of these findings to other populations of HIV‐negative infants. The early cessation of the only trial in HIV‐positive adults, resulting in reduced follow‐up from two years to minimum six months and a reduction of study sample size from 1200 to 625, led this study to be underpowered for evaluation of efficacy (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>). This may have limited the certainty of any inferences made to adults with HIV at high risk of contracting tuberculosis in terms of efficacy of MVA85A in this population. The effect of tuberculosis vaccination would be very similar regardless of geographical variation. Data from this review consistently showed no effect of the vaccine. As such, it is reasonable to generalize these findings to broader populations. For safety outcomes, the Phase 1 studies that we summarized in the <a href="#CD012915-sec-0031">Background</a> section and <a href="#CD012915-tbl-0002">Table 1</a>, included adults, children, and infants from the UK and three African countries. Most of the adverse effects related to vaccination were mild and were contained locally to the injection site. This supports the trial findings summarized in this review. </p> <section id="CD012915-sec-0095"> <h4 class="title">Certainty of the evidence</h4> <p>Overall the included studies were well‐conducted. For most of our outcomes, there were few events and broad CIs for the pooled estimates of effect which contained clinically appreciable benefit and harm or no effect (see <a href="./full#CD012915-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In the largest trial, the main reported endpoint (endpoint one) point estimate was in the direction of benefit of the vaccine on tuberculosis disease (<a href="./references#CD012915-fig-0016" title="">Analysis 2.1</a>; <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). Whether this was due to the definition of endpoints or due to statistical heterogeneity was unclear. To minimize the impact of this inconsistency we presented results for cases diagnosed microbiologically and cases defined by being started on treatment. This was felt to reflect the most specific measure of efficacy and a measure of the real‐world situation. As a result of this, the methodological uncertainties surrounding case definition did not reduce our confidence in the effect estimates. </p> <p>Failure to follow‐up participants from the start of intervention for efficacy measures in <a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> risked biasing outcomes. While it is plausible that participants with undiagnosed active tuberculosis would be inappropriately picked up, it is also plausible that participants who hypothetically could have developed tuberculosis immediately after vaccination would be excluded from analysis. However, the potential impact of this was unclear and as such we did not downgrade due to risk of bias for efficacy outcomes including this study. </p> <p>In terms of latent tuberculosis, using the online calculator at <a href="http://www.sealedenvelope.com/power/binary-noninferior/" target="_blank">www.sealedenvelope.com/power/binary‐noninferior/</a> at a significance level of 5% and with 80% power at a failure rate of 11% and a non‐inferiority limit of 5% a sample size per group of 484 would be sufficient to demonstrate non‐inferiority. Therefore, in terms of risk of developing latent tuberculosis where we had high certainty evidence that MVA85A had no important effect in reducing risk, we are confident that future trials are unlikely to change this result as we had 3831 participants in the analysis versus a minimum number of 484 participants required in each group. </p> <p>Regarding the safety outcomes, the summary of findings from the Phase I trials for MVA85A performed in adults, adolescents, and infants with 712 participants showed that most of the adverse effects related to vaccination were mild and were contained locally to the injection site, and none of the trials reported a serious adverse event attributable to the vaccine. This supports the certainty of the evidence found in this review. </p> </section> </section> <section id="CD012915-sec-0096"> <h3 class="title" id="CD012915-sec-0096">Potential biases in the review process</h3> <p>We followed standard methods in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012915-bbs2-0053" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester (UK): Available from www.handbook.cochrane.org.. ">Higgins 2011</a>). The Cochrane Infectious Disease Group Information Specialist performed a comprehensive literature search with no restriction in language to identify all eligible studies, thus it is unlikely that we missed any large studies. We were unable to formally assess publication bias as fewer than 10 studies met our inclusion criteria. </p> </section> <section id="CD012915-sec-0097"> <h3 class="title" id="CD012915-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>No previous systematic reviews have been undertaken looking at the effects of MVA85A.</p> <p>There has been much debate over the contribution of animal studies to the progression of MVA85A vaccine to trial (<a href="./references#CD012915-bbs2-0043" title="CohenD . Oxford TB vaccine study calls into question selective use of animal data. BMJ2018;360:j5845. ">Cohen 2018</a>; <a href="./references#CD012915-bbs2-0062" title="McShaneH , HillA , HatherillM , TamerisM , SheaJ , GinsbergA . Helen McShane and colleagues reply to Deborah Cohen. BMJ2018;360:k236. ">McShane 2018</a>). We systematically assessed Phase 1 and 2 data and we found no difference in tuberculosis incidence in any population, and no increase in the risk of serious adverse effects attributable to the vaccine. There was a small increase in the risk of experiencing any adverse event. </p> <p>The findings of this review are consistent in that MVA85A is not efficacious for preventing tuberculosis and that there is no evidence that the MVA85A vaccine caused any serious harm to participants in the trials during its investigation. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012915-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012915-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012915-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012915-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Comparison of endpoints, outcome: 2.1 Tameris 2013: incidence of tuberculosis according to post‐hoc endpoints." data-id="CD012915-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Comparison of endpoints, outcome: 2.1 Tameris 2013: incidence of tuberculosis according to post‐hoc endpoints. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 MVA85A Vs Placebo, outcome: 1.1 Tuberculosis confirmed by culture or Xpert® MTB/RIF longest reported follow‐up." data-id="CD012915-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 MVA85A Vs Placebo, outcome: 1.1 Tuberculosis confirmed by culture or Xpert® MTB/RIF longest reported follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.2 Active tuberculosis: started on tuberculosis treatment." data-id="CD012915-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.2 Active tuberculosis: started on tuberculosis treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.4 Adverse effects of any severity." data-id="CD012915-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.4 Adverse effects of any severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 1 Active tuberculosis (TB): confirmed by culture or Xpert® MTB/RIF longest reported follow‐up." data-id="CD012915-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 1 Active tuberculosis (TB): confirmed by culture or Xpert® MTB/RIF longest reported follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 2 Active TB: started on TB treatment." data-id="CD012915-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 2 Active TB: started on TB treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 3 Latent TB." data-id="CD012915-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 3 Latent TB.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 4 Adverse effects of any severity." data-id="CD012915-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 4 Adverse effects of any severity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 5 Adverse effects of any severity: aggregated." data-id="CD012915-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 5 Adverse effects of any severity: aggregated.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 6 Serious adverse effects." data-id="CD012915-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 6 Serious adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 7 Adverse events of any severity." data-id="CD012915-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 7 Adverse events of any severity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MVA85A versus placebo, Outcome 8 Abnormal biochemical tests." data-id="CD012915-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 MVA85A versus placebo, Outcome 8 Abnormal biochemical tests.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison of endpoints, Outcome 1 Tameris 2013: incidence of tuberculosis (TB) according to post‐hoc endpoints." data-id="CD012915-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Comparison of endpoints, Outcome 1 Tameris 2013: incidence of tuberculosis (TB) according to post‐hoc endpoints. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012915-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/urn:x-wiley:14651858:media:CD012915:CD012915-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_t/tCD012915-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison of endpoints, Outcome 2 Ndiaye 2015: incidence of TB according to post hoc defined endpoints." data-id="CD012915-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Comparison of endpoints, Outcome 2 Ndiaye 2015: incidence of TB according to post hoc defined endpoints. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/media/CDSR/CD012915/image_n/nCD012915-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012915-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">MVA85A compared to placebo for preventing tuberculosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MVA85A compared to placebo for preventing tuberculosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐positive and ‐negative adults and children<br/> <b>Setting:</b> South Africa, Senegal<br/> <b>Intervention:</b> MVA85A<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with MVA85A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active tuberculosis: confirmed by culture or Xpert® MTB/RIF</b> longest reported follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (10 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/> (0.58 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3439<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably made little or no difference to the risk of developing active tuberculosis. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active tuberculosis: started on tuberculosis treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000<br/> (94 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/> (0.92 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3687<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably made little or no difference to the risk of needing to start tuberculosis treatment. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Latent tuberculosis</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000<br/> (97 to 138) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/> (0.85 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3831<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably made little or no difference to the risk of developing latent tuberculosis. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD 0.00</b><br/> (–0.00 to 0.00)<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3692<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG did not cause life‐threatening serious adverse effects. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of any severity (local reactions of the skin)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Vaccination with MVA85A was associated with more reactions at the site of the injection.<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3187<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>h,i,j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG probably increased the risk of having an adverse reaction related to vaccination at the site of the injection. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of any severity (systemic symptoms)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Adverse events reported included malaise, lethargy, fever, and vomiting although differences between groups were not significant at a 95% CI level.<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>k,l,m</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccinating people with MVA85A in addition to BCG may not have been associated with an increase in adverse effects related to vaccination. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events of any severity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>808 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>849 per 1000<br/> (824 to 873) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/> (1.02 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3836<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>n</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccination with MVA85A alone slightly increased the risk of having an adverse event.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BCG:</b> Bacillus Calmette‐Guérin; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RD:</b> risk difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias. The largest trial was at unclear risk of bias due to selective reporting; however, the outcomes presented were unlikely to be affected by this (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>).<br/> <sup>b</sup>Downgraded by one level for imprecision. Few events and wide CIs containing clinically appreciable benefit and harm.<br/> <sup>c</sup>Not downgraded for indirectness. The only trial in HIV‐positive adults was stopped early meaning it was underpowered to detect efficacy (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>). Therefore, evidence of efficacy is more generalizable to infants; however, results in adults were consistent with little or no effect being seen across all endpoints.<br/> <sup>d</sup>Downgraded by one level for imprecision. Broad CI containing little or no effect and clinically appreciable harm.<br/> <sup>e</sup>Not downgraded for risk of bias. The largest trial was at unclear risk of bias due to selective reporting; however, the outcome of latent tuberculosis was unlikely to be affected by this (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>).<br/> <sup>f</sup>Risk difference presented as explained in our result section.<br/> <sup>g</sup>Extensive investigation of the vaccine in Phase 1 studies outlined in the <a href="#CD012915-sec-0031">Background</a> of this review outlined "a transient, superficial reaction local to the injection site and mild short‐lived viral symptoms" consistent with the findings reported in the Phase 2 trials.<br/> <sup>h</sup>Downgraded by one level for imprecision. Broad CIs containing clinically appreciable benefit and harm.<br/> <sup>i</sup>Not downgraded for risk of bias. The largest study reported local adverse events and defined these as solicited by the vaccine (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>).<br/> <sup>j</sup>Not downgraded for heterogeneity. While there might be some heterogeneity between the included trials in terms of time of outcome collection, the outcomes are consistent in favour to placebo as shown in <a href="./references#CD012915-fig-0012" title="">Analysis 1.5</a>.<br/> <sup>k</sup>Downgraded by one level for risk of bias. There were some deficiencies in the trial reporting these outcomes.<br/> <sup>l</sup>Additional safety data from Phase 1 studies in 712 participants did not show any adverse effect signals (see section in <a href="#CD012915-sec-0031">Background</a> of this review).<br/> <sup>m</sup>Downgraded by one level for imprecision. Few events reported in the largest trial (<a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>), data not disaggregated in the second largest trial (<a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a>).<br/> <sup>n</sup>Not downgraded for inconsistency. I<sup>2</sup> value of 37% judged to be non‐significant heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">MVA85A compared to placebo for preventing tuberculosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of Phase 1 studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NCT trial number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Route</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and schedule details</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (age)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0064" title="NCT00423566 . A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis, antigen 85A, delivered intradermally by a needle injection in healthy volunteers. clinicaltrials.gov/ct2/show/NCT00423566 (first received 25 August 2017). ">NCT00423566</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002–2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 adults (18–45 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 trials (112 participants); combined in 1 report: no serious AE attributable to the vaccine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0016" title="McShaneH , PathanAA , SanderCR , KeatingSM , GilbertSC , HuygenK , et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG‐primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine2004; Vol. 10:1240‐4. ">McShane 2004</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0065" title="NCT00423839 . A phase I study of the safety and immunogenicity of MVA85A in healthy Gambian volunteers. clinicaltrials.gov/ct2/show/NCT00423839 (first received 25 August 2017). ">NCT00423839</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003–2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose, 2 doses</p> <p>(5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0007" title="BrookesRH , HillPC , OwiafePK , IbangaHB , JeffriesDJ , DonkorSA , et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLOS One2008;3(8):e2921. ">Brookes 2008</a>; <a href="./references#CD012915-bbs2-0054" title="IbangaHB , BrookesRH , HillPC , OwiafePK , FletcherHA , LienhardtC , et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis‐endemic countries: issues in study design. Lancet Infectious Diseases2006;6(8):522‐8. ">Ibanga 2006</a>; <a href="./references#CD012915-bbs2-0085" title="OwiafeP , HillP , IbangaHB , BrookesRH , McShaneH , SutherlandJS , et al. Differential cytokine levels in adults induced by a novel candidate TB boost vaccine, MVA85A‐according to previous BCG vaccination status. Journal of Vaccines &amp; Vaccination2012;3(7):158. ">Owiafe 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0067" title="NCT00427830 . A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis, antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have previously received BCG. clinicaltrials.gov/ct2/show/NCT00427830 (first received 25 August 2017). ">NCT00427830</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003–2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0016" title="McShaneH , PathanAA , SanderCR , KeatingSM , GilbertSC , HuygenK , et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG‐primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine2004; Vol. 10:1240‐4. ">McShane 2004</a>; <a href="./references#CD012915-bbs2-0024" title="PathanAA , MinassianAM , SanderCR , RowlandR , PorterDW , PoultonID , et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine2012;30(38):5616‐24. ">Pathan 2012</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a>; <a href="./references#CD012915-bbs2-0034" title="WhelanKT , PathanAA , SanderCR , FletcherHA , PoultonI , AlderNC , et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLOS One2009;10(11):e5934. ">Whelan 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0066" title="NCT00427453 . A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis, antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have received BCG immunisation 1 month previously. clinicaltrials.gov/ct2/show/NCT00427453 (first received 25 August 2017). ">NCT00427453</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003–2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0024" title="PathanAA , MinassianAM , SanderCR , RowlandR , PorterDW , PoultonID , et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine2012;30(38):5616‐24. ">Pathan 2012</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0068" title="NCT00456183 . Safety and immunogenicity of MVA85A in volunteers latently infected with TB. clinicaltrials.gov/ct2/show/NCT00456183 (first received 25 August 2017). ">NCT00456183</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A, (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 adults with latent tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AEs</p> <p>7 trials (112 participants; data combined in 1 report)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>; <a href="./references#CD012915-bbs2-0027" title="SanderCR , PathanAA , BeveridgeNE , PoultonI , MinassianA , AlderN , et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis‐infected individuals. American Journal of Respiratory and Critical Care Medicine2009;179:724‐33. ">Sander 2009</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0070" title="NCT00465465 . A study of 2 doses of a new TB vaccine, MVA85A, in healthy volunteers previously vaccinated with BCG. clinicaltrials.gov/ct2/show/NCT00465465 (first received 25 August 2017). ">NCT00465465</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005–2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (1 × 10<sup>8</sup> pfu for 12 participants, and 1 × 10<sup>7</sup> pfu for 12 participants) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0050" title="GriffithsKL , PathanAA , MinassianAM , SanderCR , BeveridgeNE , HillAV , et al. Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. PLOS One2011;6(8):e23463. ">Griffiths 2011</a>; <a href="./references#CD012915-bbs2-0060" title="MatsumiyaM , StylianouE , GriffithsK , LangZ , MeyerJ , HarrisSA , et al. Roles for Treg expansion and HMGB1 signaling through the TLR1‐2‐6 axis in determining the magnitude of the antigen‐specific immune response to MVA85A. PLOS One2013;8(7):e67922. ">Matsumiya 2013</a>; <a href="./references#CD012915-bbs2-0023" title="PathanAA , SanderCR , FletcherHA , PoultonI , AlderNC , BeveridgeNE , et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLOS One2007;2(10):e1052. ">Pathan 2007</a>; <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0069" title="NCT00460590 . Safety and immunogenicity of MVA85A, in healthy volunteers in Cape Town. clinicaltrials.gov/ct2/show/NCT00460590 (first received 25 August 2017). ">NCT00460590</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005–2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 adults and adolescents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0012" title="HawkridgeT , ScribaTJ , GelderbloemS , SmitE , TamerisM , MoyoM , et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. Journal of Infectious disease2008; Vol. 198, issue 4:544‐52. ">Hawkridge 2008</a>; <a href="./references#CD012915-bbs2-0029" title="ScribaTJ , TamerisM , MansoorN , ThomasZM , GriffithsK , AntrobusRD , et al. Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. European Journal of Immunology2010;40:279‐90. ">Scriba 2010</a>; <a href="./references#CD012915-bbs2-0032" title="TamerisM , GeldenhuysH , LuabeyaAK , SmitE , HughesJE , VermaakS , et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLOS One2014;9(2):e87340. ">Tameris 2014</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0071" title="NCT00480454 . Safety, immunogenicity, and impact of MVA85A, on the immunogenicity of the EPI vaccines. clinicaltrials.gov/ct2/show/NCT00480454 (first received 25 August 2017). ">NCT00480454</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006–2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A;</p> <p>1 dose MVA85A (2.5 × 10<sup>7</sup> pfu, 5 × 10<sup>7</sup> pfu) </p> <p>Groups</p> <p> <ul id="CD012915-list-0001"> <li> <p>EPI vaccines:</p> </li> <li> <p>MVA85A + EPI:</p> </li> <li> <p>MVA85A + EPI 1 week later</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 infants (4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE judged to be related to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0021" title="OdutolaAA , OwolabiOA , OwiafePK , McshaneH , OtaMO . A new TB vaccine, MVA85A, induces durable antigen‐specific responses 14 months after vaccination in African infants. Vaccine2012; Vol. 30:5591‐4. ">Odutola 2012</a>; <a href="./references#CD012915-bbs2-0022" title="OtaMO , OdutolaAA , OwiafePK , DonkorS , OwolabiOA , BrittainNJ , et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci. Transl. Med.2011; Vol. 3:88ra56. ">Ota 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0063" title="NCT00395720 . The safety and immunogenicity of a TB vaccine; MVA85A, in healthy volunteers who are infected with HIV. clinicaltrials.gov/ct2/show/NCT00395720 (first received 25 August 2017). ">NCT00395720</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006–2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup>pfu for 10 participants, and 1 × 10<sup>8</sup> pfu for 10 participants) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0018" title="Minassian , AM , RowlandR , BeveridgeNE , PoultonID , SattiI , HarrisS , et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV‐infected adults. BrItish Medical Journal2015; Vol. 1:e000223. ">Minassian 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0072" title="NCT00480558 . A study of MVA85A, in asymptomatic volunteers infected with TB, HIV or both. clinicaltrials.gov/ct2/show/NCT00480558 (first received 25 August 2017). ">NCT00480558</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (5 × 10<sup>7</sup> pfu) </p> <p>4 groups with background of</p> <p> <ul id="CD012915-list-0002"> <li> <p>MTB</p> </li> <li> <p>HIV</p> </li> <li> <p>MTB + HIV</p> </li> <li> <p>HIV on ART</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 adults (18–50 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0030" title="ScribaTJ , TamerisM , SmitE , Van derMerwel , Jane HughesE , KadiraB , et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV‐ and/or Mycobacterium tuberculosis‐infected adults. American Journal of Respiratory and Critical Care Medicine2012;185(7):769‐78. ">Scriba 2012</a>; <a href="./references#CD012915-bbs2-0033" title="TannerR , KakalachevaK , MillerE , PathanAA , ChalkR , SanderCR , et al. Serum indoleamine 2,3‐dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. Biomed Central Infectious Diseases2014;14:660. ">Tanner 2014</a>; <a href="./references#CD012915-bbs2-0032" title="TamerisM , GeldenhuysH , LuabeyaAK , SmitE , HughesJE , VermaakS , et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLOS One2014;9(2):e87340. ">Tameris 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0074" title="NCT00653770 . A phase I study to assess the safety and immunogenicity of tuberculosis (TB) vaccine candidates FP85A and MVA85A. clinicaltrials.gov/ct2/show/NCT00653770 (first received 25 August 2017). ">NCT00653770</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007–2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP85A, MVA85A (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0026" title="RowlandR , PathanAA , SattiI , PoultonID , MatsimuyaMM , WhitakerM , et al. Safety and immunogenicity of an FP9‐vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG‐vaccinated healthy adults: a phase I clinical trial. Human Vaccines and Immunotherapeutics2013;9(1):50‐62. ">Rowland 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0073" title="NCT00548444 . T‐cell turnover following vaccination with MVA85A. clinicaltrials.gov/ct2/show/NCT00548444 (first received 25 August 2017). ">NCT00548444</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007–2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose</p> <p>(1 × 10<sup>8</sup> pfu), administered as 2 injections (5 × 10<sup>7</sup> pfu each injection) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 trials (112 participants); data combined in 1 report: no serious AE attributable to the vaccine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Porter (unpublished data: source <a href="./references#CD012915-bbs2-0025" title="RowlandR , BrittainN , PoultonID , MinnassainAM , SanderC , PorterDW , et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in vaccinology2012;1:27‐35. ">Rowland 2012</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0075" title="NCT00731471 . A phase I study of a new tuberculosis (TB) vaccine, MVA85A, in healthy volunteers with HIV. clinicaltrials.gov/ct2/show/NCT00731471 (first received 25 August 2017). ">NCT00731471</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 2 doses (spaced by 6–12 months) (1 × 10<sup>8</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Senegal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0009" title="DieyeTN , NdiayeBP , DiengAB , FallM , BritainN , VermaakS , et al. Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART plus subjects. PLOS One2013;8(6):e67177. ">Dieye 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0077" title="NCT01181856 . Safety of tuberculosis vaccine, MVA85A, administered by the intramuscular route and the intradermal route. clinicaltrials.gov/ct2/show/NCT01181856 (first received 25 August 2017). ">NCT01181856</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> <p>IM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010–2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose (1 × 10<sup>8</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0060" title="MatsumiyaM , StylianouE , GriffithsK , LangZ , MeyerJ , HarrisSA , et al. Roles for Treg expansion and HMGB1 signaling through the TLR1‐2‐6 axis in determining the magnitude of the antigen‐specific immune response to MVA85A. PLOS One2013;8(7):e67922. ">Matsumiya 2013</a>; <a href="./references#CD012915-bbs2-0017" title="Meyer , J , Harris , S.A , SattiI , PoultonID , PoyintzHC , TannerR , et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine2013; Vol. 31, issue 2013:1026‐33. ">Meyer 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0078" title="NCT01194180 . A BCG challenge model study to assess anti‐mycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A. clinicaltrials.gov/ct2/show/NCT01194180 (first received 25 August 2017). ">NCT01194180</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010–2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A, BCG;</p> <p>1 dose (1 × 10<sup>8</sup> pfu) </p> <p>Group A: BCG naive, no MVA85A<br/> Group B: BCG naive, MVA85A </p> <p>Group C: BCG vaccinated, no MVA85A</p> <p>Group D: BCG vaccinated, MVA85A.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 adults recruited; 48 completed study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE attributable to the vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>; <a href="./references#CD012915-bbs2-0052" title="HarrisSA , SattiI , MatsumiyaM , StockdaleL , ChomkaA , TannerR , et al. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. Clinical and Vaccine Immunology2014;21(7):1005‐11. ">Harris 2014b</a>; </p> <p><a href="./references#CD012915-bbs2-0060" title="MatsumiyaM , StylianouE , GriffithsK , LangZ , MeyerJ , HarrisSA , et al. Roles for Treg expansion and HMGB1 signaling through the TLR1‐2‐6 axis in determining the magnitude of the antigen‐specific immune response to MVA85A. PLOS One2013;8(7):e67922. ">Matsumiya 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0079" title="NCT01497769 . Safety of tuberculosis vaccine, MVA85A, administered by the aerosol route and the intradermal route. clinicaltrials.gov/ct2/show/NCT01497769 (first received 25 August 2017). ">NCT01497769</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol</p> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011–2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 dose: 1 × 10<sup>8</sup>, 1 × 10<sup>7</sup> pfu </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine related serious adverse effects.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0028" title="SattiI , MeyerJ , HarrisSA , ThomasZM , GriffithsK , AntrobusetRD , et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG‐vaccinated healthy adults: a phase 1, double‐blind, randomised controlled trial. Lancet Infectious diseases2014;14:939‐46. ">Satti 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0080" title="NCT01683773 . Safety study of tuberculosis vaccines AERAS‐402 and MVA85A. clinicaltrials.gov/ct2/show/NCT01683773 (first received 25 August 2017). ">NCT01683773</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012–2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AERAS‐402 MVA85A;</p> <p>Group A: 2 doses AERAS‐402 then MVA85A</p> <p>Group B: 1 dose AERAS‐402 then MVA85A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine related serious AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0031" title="SheehanS , HarrisSA , SattiI , HokeyDA , DheenadhayalanV , StockdaleL , et al. A Phase I, Open‐Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS‐402 and MVA85A, Administered by Prime‐Boost Regime in BCG‐Vaccinated Healthy Adults. PLOS One2015;10(11):e0141687. ">Sheehan 2015</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0082" title="NCT01879163 . Phase I trial evaluating safety and immunogenicity of MVA85A‐IMX313 compared to MVA85A in BCG vaccinated adults. clinicaltrials.gov/ct2/show/NCT01879163 (first received 25 August 2017). ">NCT01879163</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013–2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A IMX313;</p> <p>Group A: low‐dose MVA85A‐IMX313 (1 × 10<sup>7</sup> pfu) </p> <p>Group B: dose MVA85A‐IMX313 (5 × 10<sup>7</sup> pfu) </p> <p>Group C: MVA85A (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 BCG vaccinated adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No vaccine‐related serious AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0019" title="MinhinnickA , SattiI , HarrisS , WilkieM , SheehanS , StockdaleL , et al. A first‐in‐human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A‐IMX313, administered to BCG‐vaccinated adults. Vaccine Vol. 34, issue 2016:1412‐21. ">Minhinnick 2016</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0081" title="NCT01829490 . Safety study of ChAdOx185A vaccination with and without MVA85A boost in healthy adults. clinicaltrials.gov/show/NCT01829490 (first received 11 April 2013). ">NCT01829490</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013–2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A, ChAdOx1 85A;</p> <p>Group A: 1 dose ChAdOx1 85A</p> <p>Group B: 1 dose ChAdOx1 85A then MVA85A</p> <p>Group C: 2 doses ChAdOx1 85A then MVA85A (1 × 10<sup>8</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported yet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No publication</p> <p><a href="./references#CD012915-bbs2-0081" title="NCT01829490 . Safety study of ChAdOx185A vaccination with and without MVA85A boost in healthy adults. clinicaltrials.gov/show/NCT01829490 (first received 11 April 2013). ">NCT01829490</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0083" title="NCT01954563 . Study evaluating aerosol and intradermal administration of a candidate tuberculosis (TB) vaccine, MVA85A, as a way to increase immune response and avoid anti‐vector immunity. clinicaltrials.gov/ct2/show/NCT01954563 (first received 25 August 2017). ">NCT01954563</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol</p> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013–2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A;</p> <p>Group 1: aerosol then ID</p> <p>Group 2: ID then aerosol</p> <p>Group 3: ID then ID (5 × 10<sup>7</sup> pfu) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported yet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0058" title="ManjalyTZ , SattiI , WilkieM , HarrisS , RisteM , HamidiA , et al. A phase I trial evaluating aerosol administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti‐vector immunity. American Journal of Respiratory and Critical Care Medicine2016;193:A5487. ">Manjaly 2016</a> </p> <p>(conference abstract)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0084" title="NCT02532036 . MVA85A aerosol versus intramuscular vaccination in adults with latent Mycobacterium tuberculosis (M. tb) Infection. clinicaltrials.gov/show/NCT02532036 (first received 25 August 2015). ">NCT02532036</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol</p> <p>ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015–2018</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MVA85A; 1 × 10<sup>7</sup> pfu aerosol inhaled, </p> <p>5 × 10<sup>7</sup> aerosol and ID </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–ve</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported yet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0084" title="NCT02532036 . MVA85A aerosol versus intramuscular vaccination in adults with latent Mycobacterium tuberculosis (M. tb) Infection. clinicaltrials.gov/show/NCT02532036 (first received 25 August 2015). ">NCT02532036</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>–ve: negative; +ve: positive; AE: adverse event; ART: antiretroviral therapy; BCG: bacillus Calmette‐Guérin; EPI: Expanded Programme on Immunization; ID: intradermal; IM: intramuscular; MTB: <i>Mycobacterium tuberculosis</i>; NR: not reported; pfu: plaque‐forming unit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of Phase 1 studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events risk of bias assessment methods</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Criterion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Participant‐reported symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was monitoring active or passive?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> <p>Passive</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified monitoring as 'active' when authors reviewed participants at set time points and enquired about symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was blinding for participants and outcome assessors adequate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> <p>Inadequate</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified blinding as 'adequate' when both participants and outcome assessors were blinded to the intervention group, and the methods of blinding (including use of a placebo) were described. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was outcome data reporting complete or incomplete?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete</p> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified outcome data reporting as 'complete' when data were presented for all the time points where it was collected. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Were all participants included in reporting?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We reported the percentage of randomized participants included in adverse event reporting.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was the analysis independent of study sponsor?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>No</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it was clearly stated that the sponsor had no input to the trial analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Laboratory tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of tests undertaken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We extracted the type and number of laboratory tests were taken.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Timing of tests: was number and timing of tests adequate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified the number and timing of tests as 'adequate,' when tests were taken at baseline, plus 2 other time points within the first week after treatment, plus the last day of the study. We classified the number of test taken as 'inadequate,' if either the laboratory controls in the first week or controls at 4 weeks were not performed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reporting of test results: was reporting of test results complete?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete</p> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified reporting as 'complete' when test results of all time points were reported. For the trials with inadequate number of tests taken, we considered completeness of reporting as inconsequential, and therefore did not record a judgement. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Independence of data analysis: was data analysis independent?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>No</p> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it is clearly stated that the sponsor had no input to the trial analysis. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Adapted from <a href="./references#CD012915-bbs2-0041" title="BukirwaH , UnnikrishnanB , KramerCV , SinclairD , NairS , TharyanP . Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD006404.pub2] ">Bukirwa 2014</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events risk of bias assessment methods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Differences in tuberculosis endpoint assessment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endpoint 3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of the following criteria.</p> <p> <ul id="CD012915-list-0008"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification <i>of M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (e.g. caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by an ophthalmologist.</p> </li> <li> <p>Miliary pattern on chest x‐ray in an HIV‐negative infant.</p> </li> <li> <p>Clinical diagnosis of TB meningitis (CSF protein concentrations &gt; 0.6 g/L and pleocytosis of &gt; 50 cells/μL with &gt; 50% mononuclear cells) with features of basal meningeal enhancement and hydrocephalus on head CT. </p> </li> <li> <p>Vertebral spondylosis.</p> </li> <li> <p>1 smear or histology specimen positive for auramine‐positive bacilli from a normally sterile body site. </p> </li> <li> <p>1 of each of the following:</p> <ul id="CD012915-list-0009"> <li> <p>evidence of mycobacterial infection defined as 2 acid‐fast positive smears (each from a separate collection) that were morphologically consistent with mycobacteria from either sputum or gastric aspirate that were not found to be non‐tuberculous mycobacteria bacteria on culture; QuantiFERON‐TB Gold In‐tube test conversion from negative to positive; or tuberculin skin test ≥15 mm and </p> </li> <li> <p>radiographic findings compatible with TB defined as ≥ 1 of the following factors identified independently by ≥ 2 of 3 paediatric radiologists serving on a masked review panel: calcified Ghon focus, pulmonary cavity, hilar or mediastinal adenopathy, pleural effusion, or airspace opacification and </p> </li> <li> <p>clinical manifestations compatible with TB defined as cough without improvement for &gt; 2 weeks; weight loss &gt; 10% of bodyweight for &gt; 2 months; or failure to thrive, defined as crossing &gt; 1 complete major centile band (&lt; 97th–90th, &lt; 90th–75th, &lt; 75th–50th, &lt; 50th–25th, &lt; 25th–10th, and &lt; 10th–3rd weight‐for‐age centiles) downward for &gt; 2 months. </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Included all infants who met endpoint 1 criteria; had marginally less stringent criteria to define TB infection and household exposure." </p> <p>Any of the following numerical categories.</p> <p> <ul id="CD012915-list-0010"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification <i>of M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (such as caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by an ophthalmologist.</p> </li> <li> <p>Miliary pattern on chest x‐ray in a HIV‐negative infant.</p> </li> <li> <p>Clinical diagnosis of TB meningitis (CSF protein &gt; 0.6 g/L and pleocytosis &gt; 50/mm<sup>3</sup> with mononuclear cell &gt; 50%) <b>or</b><sup>a</sup> features of basal meningeal enhancement and hydrocephalus on head CT. </p> </li> <li> <p>Vertebral spondylosis</p> </li> <li> <p>A single smear/histology specimen positive for auramine‐positive bacilli from a normally sterile body site. </p> </li> <li> <p>1 of each of the following:</p> <ul id="CD012915-list-0011"> <li> <p>evidence of mycobacterial infection defined as:</p> <ul id="CD012915-list-0012"> <li> <p>2 acid fast‐positive smears each from a separate collection morphologically consistent with mycobacteria from either sputum or gastric aspirate that are not found to be non‐tuberculous mycobacteria bacteria on culture, or </p> </li> <li> <p>QFT conversion from negative to positive, or</p> </li> <li> <p>Tuberculin skin test <b>≥ 10 mm</b>,<sup>a</sup> or </p> </li> <li> <p><b>household contact with AFB smear positive person</b><sup>a</sup> and </p> </li> </ul> </li> <li> <p>radiographic findings compatible with TB defined as ≥ 1 of the following identified independently by at least 2 out of 3 paediatric radiologists serving on a blinded review panel: calcified Ghon focus, pulmonary cavity, hilar/mediastinal adenopathy, pleural effusion, or airspace opacification and </p> </li> <li> <p>clinical manifestations compatible with TB defined as either</p> <ul id="CD012915-list-0013"> <li> <p>cough without improvement for &gt; 2 weeks, or</p> </li> <li> <p>weight loss ≥ 10% of bodyweight for ≥ 2 months, or</p> </li> <li> <p>failure to thrive (crossing ≥ 1 entire major centile band downward) for ≥ 2 months, where the major centile bands are defined as &lt; 97th–90th, &lt; 90th–75th, &lt; 75th–50th, &lt; 50th–25th, &lt; 25th–10th, and &lt; 10th–3rd weight‐for‐age centiles. </p> </li> </ul> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants placed on treatment for TB by a health professional with the intent of treating TB regardless of whether they have met the other efficacy endpoints. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revised endpoint 1 from <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> that removed QFT conversion from the diagnostic criteria to avoid bias towards association with QFT status. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same definition as for <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of the following numerical categories.</p> <p> <ul id="CD012915-list-0014"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification of <i>M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (such as caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by ophthalmologist.</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of the following numerical categories:</p> <p> <ul id="CD012915-list-0015"> <li> <p>Isolation of <i>M tuberculosis</i> from any site. </p> </li> <li> <p>Identification of <i>M tuberculosis</i> by an approved molecular diagnostic technique from any site. </p> </li> <li> <p>Histopathology diagnostic for TB disease (such as caseating granulomas).</p> </li> <li> <p>Choroidal tubercle diagnosed by ophthalmologist.</p> </li> <li> <p>A single smear/histology specimen positive for AFB from a normally sterile body site.</p> </li> <li> <p>2 acid‐fast smears positive each from a separate collection morphologically consistent with mycobacteria from either pulmonary or gastric sampling that are not found to be non‐tuberculous mycobacteria bacteria on culture, and ≥ 1 of the following: </p> <ul id="CD012915-list-0016"> <li> <p>a compatible radiographic feature: airspace opacification, cavity, hilar or mediastinal adenopathy, or pleural effusion; </p> </li> <li> <p>a compatible clinical feature, i.e. &gt; 2 weeks of fever, night sweats, anorexia, cough, or weight loss (≥ 5 kg by history or noticeable change in clothing fit); or ≥ 1 episodes of haemoptysis. </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same definition as for <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes not specified in the methods section.</p> <p>In results, authors specified that 8 participants were diagnosed as TB:</p> <p>"of whom one was M.tb [<i>Mycobacterium tuberculosis]</i> culture positive and 7 were diagnosed on clinical/ radiographic grounds and TB contact history. Two of the TB cases were QFT positive." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>AFB: acid‐fast bacilli; CSF: cerebrospinal fluid; CT: computerized tomography; QFT: quantiFERON; TB: tuberculosis.<br/> <sup>a</sup>In <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>, endpoint 2: criteria in bold indicate where different from endpoint 1. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Differences in tuberculosis endpoint assessment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Differences between details of studies published prior to commencement and reported outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Protocol</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Published findings</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Differences between protocol and published findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stated outcomes published prior to commencement of trial that differ to published outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement of outcome as stated a priori</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement of outcome as stated in published findings</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No protocol published.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No protocol published (extended post‐trial follow‐up of <a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a>). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: blood tests <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Percentage of participants with adverse events" AEs measured up to day 28</p> <p>SAEs measured up to 6 months.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Phlebotomy for routine haematological and biochemical analysis was done at screening, before booster vaccination, and on days 7 and 28 after each vaccination." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Routine haematological and biochemical test results did not differ between study groups (data not shown)." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematological and biochemical blood tests not outlined as a measure of safety in the study protocol. Blood test findings reported unclearly. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicaltrials.gov – local, regional, and systemic AEs and SAEs which would be reported as cumulative 12‐month incidences. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Infants followed for safety end points at weeks 1, 4, 6, and 8 after MVA85A/control vaccination and thereafter, at weeks 9, 12, and 16 (corresponding to weeks 1, 4, and 8 following delayed BCG vaccination at 8 weeks of age), and at week 52." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported total events for AEs per group after MVA85A and before BCG and for whole follow‐up period. Data including for laboratory AEs were not disaggregated as prespecified. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data including for laboratory AEs were not disaggregated as prespecified.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Safety<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local and systemic AEs for the first week.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diary cards</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local and systemic AEs reported on ≥ 1 day of the first 7 days after MVA85A vaccination.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood tests (days 7, 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical and haematological tests (days 7, 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported number and percentages of participants with abnormal results and reported that, "all except one patient that had elevated liver enzymes remained unresolved by day 28." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ESAT‐6/CFP‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants converted – suggestive of TB infection but seemed to be reported as safety data not efficacy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety profile – AEs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs measured up to day 28</p> <p>SAEs measured throughout follow‐up.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Collected data on solicited and unsolicited local and systemic AEs.</p> <p>Active surveillance for SAEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs broken down by type of event and reported in supplementary material. Only local events at the injection site were considered to be related to the vaccine. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Causal relationship with AEs other than local injection site reactions was not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety profile – blood tests<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testing up to 28 days postvaccination.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Peripheral blood for routine haematological and biochemical tests was taken at screening and on day 7 and day 28 after vaccination in an initial safety cohort of at least 330 infants." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy of MVA85A<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Using an endpoint derived from epidemiological cohort surveys in BCG vaccinated infants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported – simply stated clinical endpoints 'developed.'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Composite clinical endpoints 1, 2, 3 (see <a href="#CD012915-tbl-0004">Table 3</a>) </p> <p>Microbiologically confirmed cases reported in appendix.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The "primary efficacy endpoint" was measured using an endpoint not derived from cohort studies. </p> <p>The endpoint definition differed from all other implied or reported ways of measuring efficacy in the other studies. The point estimate showed clinically significant benefit for endpoint 1 (no benefit seen at the 95% confidence level). This endpoint was reported as the main efficacy finding. All other point estimates show no clinically significant benefit or harm. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>AE: adverse events; BCG: bacillus Calmette‐Guérin; ESAT‐6/CFP‐10: early secretory antigenic‐6/culture filtrate protein‐10; SAE: severe adverse events; TB: tuberculosis.<br/> <sup>a</sup>Primary outcomes as outlined in study protocols.<br/> <sup>b</sup>Secondary outcomes as outlined in study protocols. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Differences between details of studies published prior to commencement and reported outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of monitoring and reporting of adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Participant reported adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Outcome data reporting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Laboratory tests</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Monitoring active or passive</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants or outcome assessors</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Times data collected</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Times data reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete/not complete</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage of participants reported on</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis independent of study sponsor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of tests taken</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Timing of tests and adequacy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete reporting of test results</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Independence of data analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 min, D 2, 7, 28, 84, and 168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 7, 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemistry and haematology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inconsequential</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 7, 28, and 84 after boost 3 monthly until end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematology, chemistry, virological markers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, D 7 and 28, throughout up to D 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemistry and haematology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 1, 4, 6, 8, 16, and 52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>D: day; min: minute; NR: not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of monitoring and reporting of adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Results of the different endpoints of active tuberculosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Active TB </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. "><b>Tameris 2013</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. "><b>Andrews 2017</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] "><b>Bunyasi 2017</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. "><b>Ndiaye 2015</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] "><b>Scriba 2011</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] "><b>Nemes 2018</b> </a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint 1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/1399 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/1395 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>58/2797 (2.1%) with NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/320 (1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/325 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/123 (4.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/125 (2.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint 2<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/1399 (3.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/1395 (3.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/320 (1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/325 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint 3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196/1399 (14.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177/1395</p> <p>(12.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3/100 pyo</p> <p>(95% CI 2.9 to 3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0/100 pyo (95% CI 2.6 to 3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/320 (2.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/325 (2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>CI: confidence interval; N/A: not applicable; NDD: no disaggregated data; pyo: person‐years of observation; TB: tuberculosis.<br/> <sup>a</sup>See <a href="#CD012915-tbl-0004">Table 3</a> for description of endpoints. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Results of the different endpoints of active tuberculosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects of the MVA85A vaccine</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Breakdown</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Author conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with ≥ 1 event caused by the intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with ≥ 1 event caused by the control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Detailed AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solicited AEs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Solicited adverse events were more common in MVA85A group and most were local injection site reactions." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not detailed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Infants in MVA85A arm were more likely to experience an AE than in control arm. Injection site reactions were more frequent in MVA85A recipients and mild." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>106<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>108<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injection site<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>"Desquamation significantly increased with greater vaccine dose."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tactile fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Documented fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated liver enzyme levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased white cell count</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local 1251<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local 628<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not detailed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AE: adverse event; N/A: not applicable.<br/> <sup>a</sup>Included injection reactions, mild influenza‐like symptoms, and regional lymphadenopathy.<br/> <sup>b</sup>Authors of the study reported 105 participants with at least one adverse effect in the vaccine group and 30 participants in the placebo group, where causal relationship was defined as definite.<br/> <sup>c</sup>Aggregated between three groups receiving different doses.<br/> <sup>d</sup>Included desquamation (scaling), pain, redness, and swelling.<br/> <sup>e</sup>Authors of the study reported local and systemic adverse events. Authors specified in their protocol that, "Solicited adverse events of local injection site reactions will be considered causally related to study vaccine (adverse reaction)." Therefore, we reported such adverse events as adverse effects. Causal relationship with other adverse events was not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects of the MVA85A vaccine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events summary table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Adverse events of any severity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>1120/1399 (80.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1059/1396 (75.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>321/324</p> <p>(99.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312/325</p> <p>(96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 × 10<sup>7</sup> </p> <p>pfu = 35 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 × 10<sup>7</sup> </p> <p>pfu = 70 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 × 10<sup>8</sup> </p> <p>pfu = 135 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1/36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Mild 122/123</p> <p>(99.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121/125</p> <p>(96.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Moderate 62/123</p> <p>(50.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54/125</p> <p>(3.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Severe 11/123</p> <p>(8.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/125</p> <p>(11.2%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>NR: not reported; pfu: plaque‐forming unit.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events summary table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012915-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Abnormal haematological and biochemical tests</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Haematological blood tests</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Biochemical blood tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>MVA85A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0006" title="TamerisMD , HatherillM , LandryBS , ScribaTJ , SnowdenMA , LockhartS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo‐controlled phase 2b trial. Lancet2013;381(9871):1021‐8. ">Tameris 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0001" title="AndrewsJR , NemesE , TamerisM , LandryBS , MahomedH , McClainJB , et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine2017;5(4):282‐90. ">Andrews 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0002" title="BunyasiEW , LuabeyaAK , TamerisM , GeldenhuysH , MulengaH , LandryBS , et al. Impact of isoniazid preventive therapy on the evaluation of long‐term effectiveness of infant MVA85A vaccination. International Journal Tuberculosis and Lung Disease2017;21(7):778‐83. [DOI: dx.doi.org/10.5588/ijtld.16.0709] ">Bunyasi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0003" title="NdiayeBP , ThienemannF , OtaM , LandryBS , CamaraM , DièyeS , et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV‐1: a randomised, placebo‐controlled, phase 2 trial. Lancet Respiratory Medicine2015;3(3):190‐200. ">Ndiaye 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012915-bbs2-0005" title="ScribaTJ , TamerisM , MansoorN , SmitE , van derMerweL , MauffK , et al. Dose‐finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG‐vaccinated infants. Journal of Infectious Diseases2011;203(12):1832‐43. [DOI: 10.1093/infdis/jir195] ">Scriba 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0/108<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1/36<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 × 10<sup>7</sup> </p> <p>pfu = 35 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 × 10<sup>7</sup> </p> <p>pfu = 70 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 × 10<sup>8</sup> </p> <p>pfu = 135 μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4/36</p> <p>(11%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/36</p> <p>(2.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/36</p> <p>(8.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/36</p> <p>(25%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012915-bbs2-0004" title="NemesE , HesselingA , TamerisM , MauffK , DowningK , MulengaH , et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette‐Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases2018;66(4):554‐63. [DOI: 10.1093/cid/cix834] ">Nemes 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>14/123 (11.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/125</p> <p>(10.4%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>NR: not reported; pfu: plaque‐forming unit.<br/> <sup>a</sup>Authors stated that routine haematological and biochemical test results did not differ between study groups but did not present data.<br/> <sup>b</sup>One participant had increased white cell count concurrently with an increase in alanine aminotransferase during an episode of gastroenteritis. Authors did not describe any other case of abnormal haematological test in the rest of the participant, although it was not stated explicitly. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Abnormal haematological and biochemical tests</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/full#CD012915-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012915-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">MVA85A versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Active tuberculosis (TB): confirmed by culture or Xpert® MTB/RIF longest reported follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.58, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Active TB: started on TB treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.92, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Latent TB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects of any severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Local: skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Any fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects of any severity: aggregated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events of any severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [1.02, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Abnormal biochemical tests <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.60, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">MVA85A versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012915-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison of endpoints</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tameris 2013: incidence of tuberculosis (TB) according to post‐hoc endpoints <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Ndiaye 2015: incidence of TB according to post hoc defined endpoints <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison of endpoints</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012915.pub2/references#CD012915-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012915.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012915-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012915-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012915-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012915-note-0018">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012915-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012915-note-0003">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012915\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012915\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012915\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012915\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012915.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012915.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012915.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012915.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012915.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719322480"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012915.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719322484"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012915.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de5eab8569368',t:'MTc0MDcxOTMyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 